

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Study protocol: A culturally-tailored personalizeD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus--a randomized trial (DESI-GDM)

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-072353
Article Type:	Protocol
Date Submitted by the Author:	05-Feb-2023
Complete List of Authors:	Stennett, Rosain; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact Adamo, Kristi; University of Ottawa Anand, Sonia; McMaster University, Department of Medicine; Population Health Research Institute, Bajaj, Harpreet; LMC Healthcare Bangdiwala, Shrikant ; Population Health Research Institute Desai, Dipika; McMaster University Faculty of Health Sciences, Health Research Methods, Evidence & Impact ; Population Health Research Institute Gerstein, HC; McMaster University Faculty of Health Sciences, Department of Medicine; Population Health Research Institute Kandasamy, Sujane; McMaster University Faculty of Health Sciences, Health Research Methods, Evidence & Impact Khan, Farah; Population Health Research Institute Lear, Scott; Population Health Research Institute McDonald, Sarah; McMaster University Faculty of Health Sciences, Department of Health Research Institute McDonald, Sarah; McMaster University Faculty of Health Sciences, Department of Health Research Institute Ritvo, Paul; York University, Kinesiology and Health Science Rogge, Andrea; Population Health Research Institute Schulze, Karleen; Population Health Research Institute Scherifali, Diana; McMaster University Faculty of Health Sciences, Department of Health Research Institute Scherifali, Diana; McMaster University Faculty of Health Sciences, Department of Obstetrics & Gynecology Stearns, Jennifer; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact; McMaster University, Farncombe Family Digestive Health Rese

Ke	ywords: Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, NUTRITION & DIETETICS, PUBLIC HEALTH
	SCHOLARONE [™] Manuscripts

Protocol DESI-GDM

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Study protocol: A culturally-tailored personalizeD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus--a randomized trial (DESI-GDM)

Stennett, RN¹, Adamo, K², Anand, SS^{1,3}, Bajaj, H⁴, Bangdiwala, SI^{1,3}, Desai, D^{1,3}, Gerstein, HC^{3,5}, Kandasamy, S¹, Khan, F³, Lear, SA³, McDonald, SD^{1,3,6}, Poscai, T^{3†}, Ritvo, P⁷, Rogge, A³, Schulze, KM³, Sherifali, D^{1,3,8}, Stearns, JC^{6,9}, Wahi, G^{1,10}, Williams, NC⁵, Zulyniak, MA¹¹, de Souza, RJ^{1,3}

Affiliations

¹Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

² School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada

³Population Health Research Institute, Hamilton Health Sciences Corporation, Hamilton, ON, Canada

⁴LMC Healthcare, Brampton, Ontario, Canada

⁵Department of Medicine, McMaster University, Hamilton, Ontario, Canada

⁶Obstetrics & Gynecology, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

⁷Department of Psychology, York University, North York, Ontario, Canada

⁸School of Nursing, McMaster University, Hamilton, Ontario, Canada

⁹Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada

¹⁰ Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

¹¹School of Food Science and Nutrition, University of Leeds, Leeds, United Kingdom

† Affiliation at time of preparation of manuscript

*Corresponding author: Russell J. de Souza, <u>desouzrj@mcmaster.ca</u>

BMJ Open

Protocol DESI-GDM

Abstract

Introduction: South Asians are more likely to develop gestational diabetes mellitus (GDM) than White Europeans. Diet and lifestyle modifications may prevent GDM and reduce undesirable outcomes in both the mother and offspring. Our study seeks to evaluate the effectiveness and participant acceptability of a culturally-tailored, personalized nutrition intervention on the glucose area under the curve (AUC) after a 2-hour 75g oral glucose tolerance test (OGTT) in pregnant women of South Asian ancestry with GDM risk factors.

Methods and Analysis: One hundred ninety pregnant South Asians with at least 2 of the following GDM risk factors—pre-pregnancy body mass index (BMI) >23, age \geq 29, poor-quality diet, family history of type 2 diabetes (T2DM) in a first-degree relative, or GDM in a previous pregnancy will be enrolled during gestational week 12-18, and randomly assigned in a 1:1 ratio to: 1) usual care, plus weekly text messages to encourage walking and paper handouts or 2) a personalized nutrition plan developed and delivered by a culturally-congruent dietitian and health coach; and FitBit® to track steps. The intervention lasts 6 – 16-weeks, depending on week-of-recruitment. The primary outcome is the glucose AUC from a 3-sample 75 g OGTT 24-28 weeks gestation. The secondary outcome is GDM diagnosis, based on Born-in-Bradford criteria (fasting glucose \geq 5.2 mmol/L, or 2-hour post-load \geq 7.2 mmol/L).

Ethics and Dissemination: The study has been approved by the Hamilton Integrated Research Ethics Board (HiREB #10942). Findings will be disseminated among academics and policy makers through scientific publications along with community orientated strategies.

Word count: 249

Trial Registration: ClinicalTrials.gov NCT03607799. Registered July 31, 2018Key words: Gestational diabetes mellitus, South Asian, personalized nutrition intervention

Protocol DESI-GDM

Strengths and limitations of this study:

- Our randomized controlled trial focuses on the impact of a culturally-tailored personalized dietary intervention to reduce gestational dysglycemia among South Asian pregnant women.
- The DESI GDM study builds upon the findings of previous a study which assessed barriers and facilitators of lifestyle changes to prevent GDM, as well a birth cohort study completed in a similar population such end user co-developed approaches to intervention studies improves participant engagement and buy-in.
- This study assesses exposure to the intervention only after becoming pregnant and thus the pre-pregnancy dietary intake will not be explored.

BMJ Open

Protocol DESI-GDM

Introduction

Gestational diabetes mellitus (GDM) is a condition in which a woman without existing diabetes develops high blood sugar levels during pregnancy.¹ Complications for the baby include neonatal hypoglycemia and intensive-care admission.² GDM is a strong risk factor for future type 2 diabetes (T2DM): up to 50% of women with GDM develop T2DM within 5 years of giving birth^{3 4}, and face up to seven-fold higher lifetime risk of T2DM compared with women who have a non-GDM pregnancy.^{3 5} Additionally, GDM is associated with future atherosclerosis and cardiovascular disease (CVD) in the mother and increases the risk of T2DM in offspring up to eight-fold.⁵⁻⁸

South Asians (SA), whose ancestors are from India, Pakistan, Bangladesh, or Sri Lanka, are the largest non-white ethnic group in Canada, and are at high risk of T2DM and early CVD. SA women have at least double the risk of GDM of white European women^{9 10}, and risk factors for future T2DM in the offspring including higher birthweight, more adipose tissue, and reduced insulin sensitivity, are more common in SA infants of mothers with GDM than infants born to mothers without GDM.⁹ Furthermore a low quality diet (diet higher in meat, meat dishes, processed meats, organ meats, poultry, fish, seafood, rice, fried foods, refined grains (breads and cereals), fast foods and eggs) during pregnancy increases one's odds of developing GDM (odds ratio [OR]: 1.62; 95% CI: 1.20 to 2.19).⁹ It is assumed that approximately 13% of GDM cases in SA could be prevented by a healthy diet (population attributable risk [PAR]: 12.8%).⁹

Food-based interventions show the most potential for preventing GDM.¹¹⁻¹³ A network meta-analysis (21 randomized trials during pregnancy; n=1,865 women) ¹⁴ reported that diets with reduced glycemic load and/or increased fibre intake, compared to gestational weight gain advice, improved fasting glucose levels. In another meta-analysis of randomized control trials,

Protocol DESI-GDM

Page 5 of 30

diet modification alone led to the largest reduction in risk of excessive maternal weight gain and (3 trials; n=409 women) reduced the incidence of GDM (relative risk [RR]: 0.68; 95% CI: 0.48 to 0.96), however the overall evidence rating was low to very low for the latter outcome ¹⁵. There is a need for more robust food-based intervention studies that consider additional factors in the development of GDM in order to provide optimal prevention strategies for women at higher risk of developing the condition.

Few randomized trials of the effect of diet and/or physical activity on incident GDM have been conducted. One recent randomized trial conducted in Ireland (n=565) found that an exercise and nutrition program delivered via smartphone did not reduce GDM in overweight and obese women randomized at a mean gestational age of 15.3 weeks (RR: 1.1; 95% CI: 0.71 to 1.66)¹⁶. However, this study aimed to modify only one aspect of diet, which was reducing the glycemic index. A second trial conducted in Spain (n=1000) found that a Mediterranean dietary pattern supplemented with extra virgin olive oil and pistachios, reduced the incidence of GDM (RR: 0.73; 95% CI: 0.56 to 0.95) compared with standard low-fat dietary advice ¹⁷. A third trial, Project SARAS in Mumbai, India¹⁸, was an unblinded, individually randomized controlled trial of diet to prevent GDM in women living in slums. The intervention included a daily snack made from leafy green vegetables, fruit, and milk for the treatment group, compared with lowmicronutrient vegetables (e.g., potato and onion) for the control group, on top of the usual diet. Of 6,513 women, 35% became pregnant; of these, 89% reached a gestation of 28 wks., and 50% (n=1,008) attended an OGTT. In total, 9.9% (n=100) developed GDM using the World Health Organization's 1999 defintion.¹⁹ Although there were many challenges of conducting this trial (i.e., 50% lost to follow-up), in an intention-to-treat (ITT) analysis, GDM was reduced in the treatment group (7.3% compared with 12.4% in controls; OR: 0.56; 95% CI: 0.36, 0.86; P =

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Protocol DESI-GDM

Page 6 of 30

0.008). The reduction remained significant after adjusting for pre-pregnancy adiposity and fat or weight gain during pregnancy.

In a qualitative interpretive descriptive study of barriers and facilitators to healthy eating encountered by pregnant and recently pregnant South Asian women and health care providers living and working in the Peel Region of Ontario, Canada ²⁰, women voiced several facilitators to healthy eating such as: *i*) knowledge of culturally appropriate healthy foods; and *ii*) access to a health care provider able to provide resources and support in a timely fashion. Participants also identified barriers to healthy eating, including difficulty: *i*) changing long-held cultural diet practices; *ii*) adapting standard dietary advice to personal health beliefs; *iii*) navigating food choices at family gatherings; and *iv*) accommodating meal needs of others in the household. Women expressed a desire to learn more about healthy eating to prevent diabetes during pregnancy and were keen to use mobile health technology. Health care providers identified two major challenges to providing appropriate advice to members of this community: *i*) insufficient time for counselling; and *ii*) lack of familiarity with South Asian foods. These findings are consistent with other studies of sociocultural influences on behaviour in pregnancy in South Asian women. ^{21 22}

These observations have led us to design and evaluate the effectiveness and participant acceptability of a randomized controlled trial of a culturally-tailored, personalized nutrition intervention, delivered by a health coach, on the glucose area under the curve (AUC) after a 2-hour 75-g oral glucose tolerance test (OGTT) to pregnant South Asian women at risk of GDM living in Southern Ontario, Canada. The trial protocol follows the guidelines for protocol development and reporting described by the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement (*see* Additional file 1).

Protocol DESI-GDM

Page 7 of 30

Methods

 Design: The study is a two-arm parallel RCT. The allocation ratio will be 1:1 to the intervention or usual care (control) group. The study schema diagram illustrates the referral and screening procedure (**Figure 1**).

Setting: The study will be conducted in Southern Ontario with the primary recruitment site being the Regional Municipality of Peel, which consists of three municipalities to the west and northwest of the city of Toronto: the cities of Mississauga and Brampton, and the town of Caledon. More than half of the residents of the Region of Peel identify as South Asian.²³ The region has >800 family physicians and >60 obstetricians who see approximately 5,000 South Asian women/year in the second trimester of pregnancy. Expectant women routinely attend their first visit between 12 - 18 weeks of pregnancy and then every four weeks until 30 weeks' gestation; every two weeks from 32 to 36 weeks' gestation; and once a week from 37 weeks'

Sample size: With 86 participants per group (total n = 172), the study will have 90% power to detect at least a 15% between-group difference in AUC glucose, the primary outcome, assuming 70% adherence to the intervention (i.e. goal setting, health coach contacts, food tracking) and SD of AUC glucose = 173 mmol/min ⁹. A change in glucose of at least this magnitude has been observed in trials of similar design to test fibre supplements ²⁵, high-protein ²⁶, or high-fat diets²⁷. A 10% loss-to-follow up is assumed, which is low for dietary interventions, however given the frequent expected contact with health care providers during pregnancy, the virtual nature of our intervention, and our pilot data,²⁸ it is believed to be feasible. The sample size has been inflated to 95 per group (total n = 190) to account for the expected high

Protocol DESI-GDM

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

lost-to-follow up. The study will have low power to detect a moderate treatment effect on the secondary outcome of GDM (i.e., 20-30% between-treatment difference), and higher power to detect very large treatment effects in GDM (i.e., 80% power to detect a 61% relative risk reduction). The study will look to see if GDM incidence, measured as a dichotomous outcome, is nominally improved.

Inclusion criteria: Singleton pregnant South Asian women will be enrolled between 12 - 18 weeks gestation. This timeframe avoids the early pregnancy window, when women are most likely to experience nausea, and is past the highest period of risk for spontaneous abortion. In addition to being South Asian, a high-risk ethnic group for GDM ²⁹, participants will also need to meet at least 2 GDM risk factors: age>29⁹, low diet quality (assessed with a short diet screener) ⁹ ³⁰, family history of DM/GDM during a previous pregnancy^{29 31}, or a pre-pregnancy BMI >23.⁹

Exclusion criteria: Expectant mothers with any of the following will be excluded from the study: a) pre-existing type 1 or type 2 diabetes²⁹; b) hypertension (\geq 140 mmHg systolic or \geq 90 mmHg diastolic) or on medication for the condition³²⁻³⁴; c) serious difficulty understanding health information in English, based on the screening conversation, that would preclude informed consent and participation (93% of Canadian South Asian women in the National Household Survey could conduct a conversation in one or both official languages (English and French) ^{35 36}; d) those unwilling or unable to modify their eating habits, based on a screening question; e) those at high risk of adverse pregnancy outcomes other than GDM (e.g., twins or higher-order multiples^{32 37}, use of fertility treatments³⁸, history of hypertension/pre-eclampsia, history³⁴ of placenta previa³⁹ or pre-term delivery⁴⁰); or f) enrolment in another intervention study that would compromise full participation in the DESI-GDM) trial.

Protocol DESI-GDM

Recruitment: Because of the COVID-19 pandemic, and the university research policies the study recruitment was delayed but began in November 2021 and is expected to be completed by March 2024. The study team will provide study information to primary care physicians and obstetricians who will identify and refer participants into the study.

Randomization and blinding: Women will be randomized 1:1 to intervention or control using a centralized integrated web response system (IWRS) at the Population Health Research Institute (PHRI) in Hamilton, Ontario. A statistician will generate a randomization list using a permuted blocks algorithm with randomly chosen block sizes to ensure balance in numbers and avoid predictability.⁴¹ The nature of the intervention precludes blinding of the participants to the treatment assignment, however, those providing the analysis of blood glucose levels for assessing the primary and secondary outcomes will be blinded to treatment assignment.

At the baseline visit, the research assistant (RA) will confirm eligibility and obtain consent, either in person, verbally via telephone or web conferencing, or electronically via REDCap. These three options are believed to be flexible and responsive to participant preference, and possible regulations regarding COVID-19 public health measures. After confirming eligibility and the informed consent discussion, the RA will collect baseline measures.

After collecting baseline physical measures, the study personnel completing the visit will activate the IWRS to randomly allocate participants to control or intervention in a concealed fashion using a computer-generated random sequence. Those assigned to the intervention will be assigned to a health coach, who will contact the participant for a baseline nutrition assessment, and goal-setting session. Planned assessment visits take place at 3 time points regardless of the BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Protocol DESI-GDM

study arm: 1) baseline 12 – 18 weeks gestation; 2) follow-up 24–28 weeks of gestation; and 3) post-delivery – pregnancy and birth outcomes.

Intervention

In our intervention study which seeks to address behavioral changes, we used goal setting, behavioral contracting through bi-weekly checkups, and tailored health communication (text messaging). These strategies were drawn from the Social Cognitive Theory of behavioral changes⁴² and applied stages of change construct of the Transtheoretical Model⁴³. The activities used in the intervention are guided by the findings of 1) the START birth cohort study⁹, which identified diet as a key modifiable risk factor for GDM, and 2) a qualitative study of barriers and facilitators to healthy eating encountered by pregnant and recently pregnant South Asian women and health care providers living and working in Ontario²⁰.

Duration: Treatment/ intervention duration will be between 6 and 16 weeks, depending on the gestational age at enrollment. Effects of dietary intervention on glycemic endpoints are detectable in \leq 6 week^{44 45}, and reach maximal effectiveness after 8-10 weeks (~2 months) of intervention⁴⁶. In-person or Zoom study visit contact will occur 2 times: once for the baseline visit and once for the OGTT. Between these visits, all participants receive weekly text messages, and intervention participants will also have bi-weekly telephone or video conferencing (Zoom/WhatsApp).

Treatment group: A personalized nutrition plan will be developed for each woman by a culturally-congruent dietitian. Our dietary intervention will focus on:

i) providing personalized food recommendations that consider a woman's current dietary habits by identifying food choices and substitutions that will optimize the diet;

- *ii)* providing dietary advice that is sensitive to religious belief/practice if desired by the participant (e.g., vegetarian foods maybe preferred by *Hindu*, *Buddhists*, *Jainists*; etc.; while inclusion of meat may be more appropriate for *Sikhs* and *Christians*) and regional (e.g., Northern vs. Southern India, Sri Lanka, Bangladesh, Pakistan) culinary practices; and
- *iii)* involving the household meal preparer, if this is not the participant herself, in the coaching contacts; and use mobile health technology to reduce the amount of in-office time a health care practitioner spends on dietary counselling. Additionally, participants assigned to the intervention group will be given a Fitbit to track their steps along with encouragement to increase walking.

The health coach will co-design a plan with each participant that considers baseline dietary intake, energy balance for recommended gestational weight gain, personal values, and preferences, and set 2-4 "SMART" goals. Nutrition and behaviour change experts have developed text messages that support 11 categories of nutrition goals (Table 1), targeted to address eating behaviours identified by participants in our qualitative study, designed to optimize energy balance for weight gain and improve dietary quality.

Table 1. Categories of nutrition goals

1.	Eating out healthy	2.	Reduce indulgence in sweets/desserts
3.	Controlling over-eating	4.	Reduce intake of sugary beverages
5.	Reducing high-fat, fried foods	6.	Cooking meals at home more
7.	Reducing highly refined carbohydrates	8.	Improving meal planning

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protocol DESI-GDM

9. Encouraging mindful eating	10. Eating more fruits and vegetables
11. Increasing quality protein intake	

Both groups: Participants in both groups receive weekly text messages, aimed at increasing walking, as this was identified as a way to increase physical activity during pregnancy that was acceptable to South Asian women to undertake during pregnancy,²⁰ and is critical for glucose homeostasis during pregnancy.^{47 48} Both groups will be given resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy(paper handouts) plus additional materials adapted specifically for the South Asian community. Health care providers in Peel Region use these tools routinely (Diabetes Canada: https://bit.ly/2m8r2tT; or Heart & Stroke: https://bit.ly/2lDubl7).

Study Measurements and Schedule

Baseline assessment (for both intervention and control participants): At the baseline visit, participants' physical measurement (height, weight, blood pressure, skinfold thickness and midupper arm circumference), fasting urine and blood sample will be collected. Additionally, an ayurvedic assessment and 3 questionnaires (baseline instrument, INTERHEART Food Frequency Questionnaire (FFQ) and COVID-19 and vaccine questionnaire) will be administered. The baseline instrument is researcher developed and has 4 sections: 1. Socio-demographics; 2. medical history; 3. obstetric history; and 4. lifestyle history.

The Ayurvedic "prakriti" assessment is a way of characterizing a population into set subgroups, based on traditional Indian medicine called Ayurveda. This is a method of taking a person-centered approach to health care⁴⁹, based on phenotypic characteristics such as

BMJ Open

Protocol DESI-GDM

Page 13 of 30

appearance, mannerisms, etc. and is used for personalizing medicine and ways of healthy living for individual. We will use the validated TNMC questionnaire from 2004.⁵⁰ The decision to use this tool was taken during the development of the protocol, through conversations with members of the team and potential participants who practice Ayurveda. We may explore differences in the primary outcome according to prakriti, however these are post-hoc, exploratory analyses only.

The INTERHEART FFQ (modified for use in pregnancy) is a semiquantitative food frequency questionnaire (FFQ) that assesses intake of fruits and vegetables, and fast foods consumption. The FFQ was adapted from the 19-item INTERHEART FFQ ⁵¹, which has been used in studies that included South Asians.^{52 53}

The COVID-19 and vaccine questionnaire a short two-part, self-administered questionnaire. We have decided to administer this because the COVID-19 pandemic has impacted all aspects of day-to-day life, and its impact on our participants will help contextualize our findings. The first part is the Vaccination Attitudes Examination (VAX) scale⁵⁴, a validated, and reliable tool that assesses general vaccination attitudes across 4 domains: 1. Mistrust of vaccine benefit; 2. Worries about unforeseen future events; 3. Concerns about commercial profiteering; and 4. Preference for natural immunity. The second section comprises additional questions about preferred types of vaccines, preferred location of receiving the vaccine, and general attitudes/concerns about vaccines.

Participants will be given an option to provide their health card number, which will enable future linkage with administrative data sources from Ontario such as the Institute for Clinical Evaluative Sciences (ICES) for potential health economic evaluation and for long-term follow-up of the mother and her child.

BMJ Open

Protocol DESI-GDM

Page 14 of 30

Weekly and Health Coach Visit: Participants in both control and intervention groups receive 1 text message every week up to the date of the OGTT with 1 of the 6 walking tips, sent by an automated outbound messaging system developed by MemoTXT (Toronto, ON). The intervention group only will also be sent weekly text messages to reinforce individual nutrition goals at times of day requested by the participant. Participants assigned to the intervention group will be given a Fitbit to track their steps; and will be requested to track food consumption in Bitesnap, a photo food journal app, for 2 weekdays and 1 weekend day bi-weekly (up to 8 assessments). Health coaches will be able to view both Fitbit and Bitesnap data via the Health Coaching Platform.

Coaching contacts to the intervention group will be made bi-weekly up to the date of their OGTT. These coaching calls will be recorded using an audio recording device. At each scheduled contact, intervention participants review agreed-upon diet goals, and assess, on a Likert scale, how often they were able to achieve the goals (ranging from "never" to "all of the time"); the coach will work with the participant to overcome barriers using our Brief Action Planning Guide. After each coaching call, participants and Health Coaches will complete a Visit Reflection questionnaire.

The central coordinator will review data regularly for completion, and *ad* hoc calls may be made to clarify items for either arm, but no counseling is provided to control group participants (see Table 2 for details).

Table 2.	Schedule	of study	activities
----------	----------	----------	------------

Activity	Baseline Visit	Weekly	Health Coach Visits (bi- weekly)	OGTT Visit	Post-Birth Follow-up
Screening	Х				
Informed Consent	X				
Randomization	X				

Page 16 of 38

Activity	Baseline Visit	Weekly	Health Coach Visits (bi- weekly)	OGTT Visit	Post-Birth Follow-up
Physical Measures (height, weight, blood pressure, skinfold thickness, mid upper arm circumference)	X				
INTERHEART Food Frequency Questionnaire	X			X	
Finger Stick for Glucose	X				
75-g OGTT				X	
Urine Sample Collection	X			X	
Blood Sample Collection (optional)	X			X	
Baseline Questionnaire	X				
Ayurvedic Assessment	X				3
Device Identification*	X				
<i>FitBit</i> Distribution*	X				
Bitesnap Downloaded*	X				
Resource Handouts	X				
Walking tips via <i>MemoTXT</i>		Х			
Diet reinforcement via MemoTXT*	4	Х			
Calls With Health Coach (set and review SMART goals, Brief Action Planning Guide) *	~		X		
Visit Reflection*			X		
Bitesnap Food Journal*		X			
FitBit Return*				X	
Exit Questionnaire				X	
Mother-reported Infant Physical Measures		2			X
Intervention group only					od
Follow-up Assessment/ Second Visit: At t	the second c	linic visit (2	24-28 weeks gesta	ation),	
NTERHEART food frequency questionna	aire, fasting	urine samp	e collection and f	fasting blo	od
ample collection are repeated (this may b	e done virtu	ally, or in-p	erson) and a 75-g	OGTT is	c

performed. Additional blood samples will be collected at 3-time points (0 hr, 1 hr and 2 hr)

during the OGTT (based on referral and participant willingness) and stored for future analysis.

BMJ Open

Protocol DESI-GDM

Page 16 of 30

In Peel, pregnant women usually undergo a 50-g glucose challenge at 24-28 weeks, with a 1-h value \geq 7.8 mmol/L being an indication for a 75-g OGTT.⁵⁵ Rather than this 2-step process, we have chosen to administer the 75- g OGTT to all women because: 1. it was used to establish South Asian-specific diagnostic criteria for GDM, and thus the study's outcomes will be directly comparable ¹⁰; 2. it avoids the high false-negative rate of the 50-g Glucose Challenge Test (GCT) among South Asians^{56 57}; 3. one-step screening has potential for long-term cost-saving⁵⁸⁻⁶⁰; and 4. Diabetes Canada recognizes that the one-step strategy can identify a subset of women who would not otherwise be identified as having GDM and who may benefit with regard to certain perinatal outcomes ²⁹. The study team will coordinate with the health care provider to ensure participants receive the 75-g OGTT between 24-28 weeks, avoiding the two-step screen.

At the completion of their OGTT, each woman will be asked to complete the DESI-GDM exit survey. This is a 9-item questionnaire based on previous tools created and used by the study team. Responses to each question are provided using a 5-item Likert scale (Strongly Disagree through Strongly Agree).

Postnatal Assessment: Study participants will be contacted after delivering their baby to self-report the birth weight and length of their baby. Participants will also be asked to provide details of any complications during delivery.

Study outcomes

The primary clinical outcome of this trial is the area under the glucose curve (AUC) of the 3sample OGTT. A measure of glycemic response, glucose AUC is a continuous measure of the response to a 75-g OGTT that accounts for variations in fasting plasma glucose levels between individuals. It is calculated by the trapezoidal method using the fasting, 1-hour, and 2-hour

Page 18 of 38

glucose⁶¹ (**Figure 2**). The AUC is superior to a single measure, i.e., fasting or 2-hour glucose only, which may not provide complete information regarding plasma glucose processing after a load.⁶²

The secondary outcome is GDM, classified using the cut-offs derived in the Born-in-Bradford (BiB) cohort, which were found to be associated with 75% higher risk of LGA or infant adiposity [infant birth weight >90th percentile for gestational age or adiposity (sum of skinfold measurements >90th percentile for gestational age) in a study of 5,408 SA women]. These values are fasting glucose \geq 5.2 mmol/L, or 2-hour post-load \geq 7.2 mmol/L ¹⁰. Current clinical cut-offs for the 75-g OGTT used to diagnose GDM in the general population as defined by the Diabetes Canada's clinical practice guidelines are: fasting glucose \geq 5.3 mmol/L, 1-hour \geq 10.6 mmol/L,

or 2-hour \geq 9.0 mmol/L.²⁹ The study team will assess the sensitivity and specificity of the BiB definition against the International Association of the Diabetes and Pregnancy Study Groups (IASPSG) or World Health Organization (WHO) criteria (see Table 3 for diagnostic criteria).

Table 3. Diagnostic criteria for secondary outcome, gestational diabetes mellitus (GDM)

Threshold	Fasting	1-h	2-h
BiB	>=5.2	-	>=7.2
IADPSG	>=5.1	>=10.0	>=8.5
WHO	>=7.0	-	>=7.8
Diabetes Canada	>=5.3	>=10.6	>=9.0

Planned data analysis

The study will assess the main effect of the diet intervention (β 1) based on two outcomes as well as conduct process and acceptability assessments:

BMJ Open

Protocol DESI-GDM

Table 4. Analysis Plan: objectives, outcome, hypothesis, and methods of analysis

Protocol DESI-GD	М			Page 18 of 30		
a) Primary clinical	outcome: The study	will assess the mai	n effect of the diet interv	Page 18 of 30 BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Down vention (β1) ention as the ervention Protected by copyright, including for uses relignements intervention s and is Method of analysisted of the component of the c		
on the primary outcome of glucose AUC with a linear regression model with <i>intervention</i> as the						
main effect (a dumr	ny variable, where 1	=treatment; 0=contr	rol).	blishe		
b) Secondary clinic	al outcome: The stu	idy will assess the m	nain effect of the diet int	ervention P as		
$(\beta 1)$ on the seconda	ry outcome of GDM	I by fitting a logistic	regression model with	intervention		
as the main effect (a	a dummy variable, w	where 1=treatment; 0	=control).	by co		
Table 4 provides a s	summary of the plan	ned analysis objecti	ves, outcome, hypothesi	ervention Protected by copyright, including for uses and is		
methods of analysis	, and Figure 3 is ou	r proposed CONSO	RT flow diagram.	23-072: t, inclu		
				ading f		
Table 4. Analysis I	Plan: objectives, ou	tcome, hypothesis,	and methods of analys	is Or May		
Objective	Outcomes	Measurement	Criteria for success	Method of analysisaters		
Primary clinical	Glycemic response to the 75-g oral glucose tolerance test	Area under the curve of glucose	Mean statistically significant reduction of 15% in the intervention arm	Linear regression*		
Secondary clinical	Gestational diabetes diagnosed by 75- g oral glucose tolerance test	Fasting glucose ≥5.2 mmol/L, or 2-hour post 75-g load ≥7.2 mmol/L	OR < 0.9 = signal of benefit OR > 1.1 = signal of harm	Linear regression* d to text and Logistic regression data mining, A		
Acceptability	Acceptability	Answer to the question "Would you recommend this program to a friend?"	≥80% of participants reply "agree or strongly agree"	Descriptive statistic raining (proportion) and similar technologies ots. y and include		
*Mixed models will	be considered to ac		ts using random intercep	pts. a June		
monthly process fee	edback (e.g., recruitr	nent, retention, adhe	be presented descriptivel erence), which the team The study team will revi	will discuss ' g		
qualitative and quar	ntitative data to refin	e implementation p	rocesses. Acceptability v	will be ographique		
For	peer review only - http:	//bmiopen.bmi.com/sit	e/about/quidelines.vhtml	e de		

 explored using semi-structured exit interviews after the OGTT visit, which allow each participant to reflect on their experiences with the program and convey what they liked and disliked about the study, and if they would recommend the program to a friend, as we have in previous studies of similar design.^{63 64}

e) Handling of missing outcome data: Missing outcome data (OGTT) will be handled via multiple imputation as a sensitivity analysis if we have >30% missing outcome data.

f) Sensitivity analyses (for primary and secondary outcomes only): The study team anticipate possible variation in treatment effect according to time in study and by clinic site (if multiple clinics refer participants). Women will be enrolled in the study between weeks 12-18 of pregnancy. The outcome will be assessed at week 24-28 of pregnancy. Therefore, the length of time that each woman will receive the intervention may vary. The first sensitivity analysis will adjust the primary outcome for time in study (OGTT date minus enrolment date). The second sensitivity analysis, if there is multiple sites of enrolment, the study team will consider a random effect of study site.

d) Interim data analysis: No interim data analysis is planned.

Ethical considerations

The study has been approved by the Hamilton Integrated Research Ethics Board (HiREB #10942), and the trial is registered with clinical trials.gov (NCT03607799). Participants will provide written, verbal, or electronic informed consent. If providing verbal consent, participants will be sent the full consent via email or paper mail, to read and refer to while being consented. If providing electronic consent via Research Electronic Data Capture (REDCap), participants will be sent a link that contains the full consent and will review the consent over telephone or web-conferencing with study staff. The participant will select whether they agree to participate at

Protocol DESI-GDM

the bottom of the consent page. Participant data will be deidentified to protect confidentiality and will only be reported and published in aggregate. Any modifications made to the study protocol will be shared with HiREB as stipulated and we will follow their advice regarding implementation and dissemination.

BMJ Open

Data monitoring and management

Study Coordination and Management: The principal investigator will take responsibility for the oversight of the study. The coordinating centre for the trial will be Population Health Research Institute (PHRI) in Hamilton, ON. The coordinating centre, under the direction of the study statistician, will receive all data, and take process steps to reduce missing data. A junior project manager, along with a graduate student will oversee the of recruitment of participants and handle central trial coordination. At weekly meetings, the study will review recruitment, minor adverse events, study inventories, and review any expressed concerns by participants or the team. The steering committee will direct operational/process, nutrition, coaching, and statistical aspects of the trial.

Data and Safety Monitoring: For a previous pilot study, the study team had convened a Data and Safety monitoring committee (DSMC), consisting of two internal medicine specialists (one being an experienced endocrinologist), and a biostatistician. This committee advised that a DSMC was not required for the pilot, voting for a safety officer, and disbanded. The committee advised the same for this trial. Therefore, at pre-specified meeting times, the safety officer, trained in internal medicine, will review data, noting any of the 8 minor (mother – induced labour, anemia, urinary tract infection, fall/injury/accident related to study, low mood or high blood pressure; child - premature labour (<36 weeks) or shoulder dystocia), or 6 major maternal

BMJ Open

Protocol DESI-GDM

Page 21 of 30

Page 22 of 38

events (hyperemesis gravidarum, caesarean section, pre-eclampsia, primary post-partum hemorrhage >500mL, miscarriage or maternal mortality,); or 2 major infant events (mortality – (fetal and neonatal) or stillbirth). The safety officer will determine whether they are related to study participation. To evaluate safety outcomes, maternal blood pressure at baseline and the OGTT follow-up visit will be measured, and notes of any pregnancy complications at coaching contacts.

The safety officer will review an interim data analysis, comparing a) mean AUC glucose; and b) GDM incidence between treatment and control (blinded) after the first 25 participants have completed their OGTT visit. Thereafter, the safety officer will review the data following each additional 50 participants. There is no early stopping rule for this study. The study will only collect data at baseline and the OGTT visit.

Patient and Public Involvement

The study included recently pregnant SA women living in Peel (ON), public health practitioners, and primary care providers that work with pregnant SA women in the development of our intervention through focus groups and semi-structured interviews. The co-investigators who work with the SA community and serve on guidelines committees have been closely involved with developing this research proposal. The study's physician collaborators will be involved in the recruitment progress, to help troubleshoot challenges, and refine intervention implementation strategies during the grant cycle.

Dissemination plans

The findings of the study will be important in guiding future evidence-based recommendations and public health policies to manage gestational glycemia in pregnant women at risk of GDM.

BMJ Open

Protocol DESI-GDM

Page 22 of 30

Throughout the study, a strategy for integrated Knowledge Translation will be used to develop a series of digital projects (short digital story-based videos) that capture: 1. participant experiences that include key messages about successful approaches to healthy eating that women would like to share with their communities; and 2. key study findings regarding effective dietary changes to reduce risk of GDM, and public health messages tailored for researchers, practitioners, and policy makers. A community event will be organized to share participant results with the group. The study team involved community organizations that they have worked with over the past 10 years to engage the SA community and health care professionals. The study will disseminate its findings among academics and policy makers using traditional methods including scientific publications, and if indicated, guideline development. The study will collaborate with family physicians, Region of Peel Public Health, and Diabetes Canada through talks and briefing reports to disseminate to community partners and Health Canada, Diabetes Canada, Heart and Stroke, Canadian Medical Association, as well as targeted communication. Peel Public Health supports "scale-up" of individual interventions using population health methods that complement clinician efforts, including mass media, social media, and text messaging campaigns. If the study demonstrate that providing tailored, culturally specific dietary advice during pregnancy to SA women is feasible and effective, the study foresee adapting the approach to other at-risk populations, including White European, African Canadian, or First Nations communities.

Discussion and implications

This study protocol describes the first RCT that examines the effect of a culturally tailored, personalized nutrition intervention on gestational glycemia in South Asian women living in Canada. In addition to proximal complications for the newborn, including life-threatening low

BMJ Open

Protocol DESI-GDM

Page 23 of 30

blood sugar (hypoglycemia) and intensive-care admission, GDM is a risk factor for future atherosclerosis and cardiovascular disease (CVD) in the mother and childhood adiposity, type 2 diabetes, and cardiovascular disease in her offspring.²⁸ Over the past two decades, studies have shown that starting interventions as early as infancy and perhaps before - may be an especially effective approach to maintaining lifelong heart health.⁶⁵ This intervention in pregnancy, aimed at reducing glycemia and its effect on the newborn infant, has great potential to "break the cycle" of maternal hyperglycemia and excess infant adiposity and insulin resistance, and eventually cardiovascular disease in both mother and baby.

Previous intervention studies that have sought to reduce the risk of GDM have reported mixed results, perhaps due to population heterogeneity of the maternal metabolic profile, inconsistent application of GDM diagnostic criteria, along with varied implementation.^{11-13 66}

The DESI GDM study is unique because it is culturally tailored for South Asian pregnant women living in Canada, and it builds upon a qualitative study of the barriers and facilitators of lifestyle changes to prevent GDM ²⁰, as well a birth cohort study completed in a similar population.⁶⁷ Such culturally tailored and participant/end user co-developed approaches to intervention studies improve engagement, by adding relevance to the intervention for participants.^{68 69} By involving the members of the community likely to benefit from the intervention in the design of the study through previous and ongoing work, the DESI-GDM intervention is tailored to the needs and challenges of participants and is feasible. The study team's connections with family physicians help encourage high rates of recruitment and engagement as well as transferability and scale-up, as appropriate, of study results.

A limitation of the study is that participants in our study will be exposed to the intervention only after becoming pregnant. Some researchers have posited that GDM prevention

BMJ Open

Protocol DESI-GDM

measures are most effective prior to pregnancy so that modifiable risk factors can be "optimized" prior to pregnancy.⁷⁰ However, an umbrella review by Giannakou, et al. ⁷¹ found that among 61 risk factors for GDM, pre-pregnancy BMI was associated with increased risk of GDM, and the authors assessed the level of evidence to be "highly suggestive". Furthermore, a prevalence meta-analysis of 70 studies involving 671 945 women found that every 1-unit increase in pre-pregnancy BMI increased the prevalence of GDM by 0.92% (95% CI: 0.73 to 1.10).⁷²

The study is unique in that it is designed to deliver and test the uptake of a dietary intervention to reduce gestational dysglycemia in a high-risk population in Canada. This intervention in pregnancy, aimed at reducing dysglycemia, has great potential to "break the cycle" of maternal gestational dysglycemia and excess infant adiposity and insulin resistance, and eventual CVD and T2DM, both of which are complications of GDM in both mother and baby.

Acknowledgements

None.

Contributorship statement

RNS drafted the manuscript. RJdS, KA, SSA, HB, SIB, HCG, SK, SAL, SDM, PR, DS, and GW conceived and designed the study. RJdS, HB, SIB, DD, FK, TP, AR, KMS, DS, JCS, NCW participated in the development of the protocol and data acquisition methods. RJdS, KMS, and SIB developed the statistical analysis plan. RJdS, DD, FK, TP, AR, KMS, DS participated in the design of the visits. All authors read and approved the final manuscript.

Funding Statement

This study is funded by The Canadian Institutes of Health Research (CIHR) application # 426250 (Project Grant), with additional support from the Population Health Research Institute (PHRI) - Digital Health Initiative and Hamilton Health Sciences (HHS) - New Investigator Fund.

Competing interests

RJ de Souza has served as an external resource person to the World Health Organization's Nutrition Guidelines Advisory Group on trans fats, saturated fats, and polyunsaturated fats. The WHO paid for his travel and accommodation to attend meetings from 2012-2017 to present and discuss this work. He has presented updates of this work to the WHO in 2022. He has also done contract research for the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism, and Diabetes, Health Canada, and the World Health Organization for which he received remuneration. He has received speaker's fees from the University of Toronto, and McMaster Children's Hospital. He has held grants from the Canadian Institutes of Health Research, Canadian Foundation for Dietetic Research, Population Health Research Institute, and Hamilton Health Sciences Corporation as a principal investigator, and is a co-investigator on several funded team grants from the Canadian Institutes of Health Research. He has served as an independent director of the Helderleigh Foundation (Canada). He serves as a member of the Nutrition Science Advisory Committee to Health Canada (Government of Canada), and a coopted member of the Scientific Advisory Committee on Nutrition (SACN) Subgroup on the Framework for the Evaluation of Evidence (Public Health England). S Kandasamy received a CIHR video talks Prize for the Knowledge Translation (KT) video created for the South Asian Grandmothers Qualitative Substudy. She was also funded by a CIHR Vanier Doctoral scholarship to develop and evaluate the SMART START KT tools. Gita Wahi has held grants from the Canadian Institutes of Health Research, and she is currently the recipient of a Research Early Career Award from Hamilton Health Sciences Foundation. P Ritvo is currently funded by the Canadian Institutes of Health (CIHR) (2021–2025). He coordinates research with NexJ Health, Inc., which provides a software platform to convey the psychosocial and psychiatric programming he develops and assesses. Ritvo receives no personal compensations for studies coordinated with NexJ but does receive free-of-charge platform support. All other authors declare no conflicts of interest.

Availability of data and materials

The principal investigator Russell de Souza will have access to the final trial data set. Any data required to support the protocol can be supplied on request.

Ethics declarations

The study has been approved by the Hamilton Integrated Research Ethics Board (HiREB #10942).

References

- 1. National Institute of Diabetes and Digestive and Kidney Diseases. Gestational diabetes 2017 [updated May 1, 2017. Available from: <u>https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational</u> accessed 5 March 2018.
- Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358(19):1991-2002. doi: 10.1056/NEJMoa0707943
- 3. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preceonception to the postnatal period London, UK2018 [Available from: https://www.nice.org.uk/guidance/ng3/chapter/2-research-recommendations#postnatal-treatment-for-women-diagnosed-with-gestational-diabetes accessed 5 March 2018.
- 4. Lee AJ, Hiscock RJ, Wein P, et al. Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. *Diabetes Care* 2007;30(4):878-83. doi: 10.2337/dc06-1816 [published Online First: 2007/03/30]
- Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* 2009;373(9677):1773-9. doi: 10.1016/S0140-6736(09)60731-5
- 6. Gunderson EP, Chiang V, Pletcher MJ, et al. History of gestational diabetes mellitus and future risk of atherosclerosis in mid-life: the Coronary Artery Risk Development in Young Adults study. *Journal of the American Heart Association* 2014;3(2):e000490. doi: 10.1161/JAHA.113.000490
- Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and prediabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. *Diabetes Care* 2008;31(2):340-6. doi: 10.2337/dc07-1596
- 8. Archambault C, Arel R, Filion KB. Gestational diabetes and risk of cardiovascular disease: a scoping review. *Open Med* 2014;8(1):e1-9. [published Online First: 2014/07/11]
- Anand SS, Gupta M, Teo KK, et al. Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. *CMAJ Open* 2017;5(3):E604. doi: 10.9778/cmajo.20170027
- Farrar D, Fairley L, Santorelli G, et al. Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort. *The Lancet Diabetes & Endocrinology* 2015;3(10):795-804. doi: 10.1016/S2213-8587(15)00255-7
- 11. Madhuvrata P, Govinden G, Bustani R, et al. Prevention of gestational diabetes in pregnant women with risk factors for gestational diabetes: a systematic review and meta-analysis of randomised trials. *Obstet Med* 2015;8(2):68-85. doi: 10.1177/1753495X15576673
- 12. Rogozińska E, Chamillard M, Hitman GA, et al. Nutritional Manipulation for the Primary Prevention of Gestational Diabetes Mellitus: A Meta-Analysis of Randomised Studies. *PLOS ONE* 2015;10(2):e0115526. doi: 10.1371/journal.pone.0115526
- Song C, Li J, Leng J, et al. Lifestyle intervention can reduce the risk of gestational diabetes: a meta-analysis of randomized controlled trials. *Obesity Reviews* 2016;17(10):960-69. doi: 10.1111/obr.12442

BMJ Open

- 14. Ha V, Bonner AJ, Jadoo JK, et al. The effects of various diets on glycemic outcomes during pregnancy: A systematic review and network meta-analysis. *PLOS ONE* 2017;12(8):e0182095. doi: 10.1371/journal.pone.0182095
- 15. Thangaratinam S, Rogozińska E, Jolly K, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. *BMJ* 2012;344:e2088. doi: 10.1136/bmj.e2088
- 16. Kennelly MA, Ainscough K, Lindsay KL, et al. Pregnancy Exercise and Nutrition With Smartphone Application Support: A Randomized Controlled Trial. *Obstetrics & Gynecology* 2018;131(5) doi: 10.1097/AOG.00000000002582
- 17. Assaf-Balut C, García de la Torre N, Durán A, et al. A Mediterranean diet with additional extra virgin olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): A randomized controlled trial: The St. Carlos GDM prevention study. *PLOS ONE* 2017;12(10):e0185873. doi: 10.1371/journal.pone.0185873
- 18. Sahariah SA, Potdar RD, Gandhi M, et al. A Daily Snack Containing Leafy Green Vegetables, Fruit, and Milk before and during Pregnancy Prevents Gestational Diabetes in a Randomized, Controlled Trial in Mumbai, India. *The Journal of Nutrition* 2016;146(7):1453S-60S. doi: 10.3945/jn.115.223461
- 19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. In: World Health Organization, ed. Geneva, SUI, , 1999.
- 20. Kandasamy S, Nguyen L, Desai D, et al. Barriers to, and Facilitators of, Lifestyle Changes to Prevent Gestational Diabetes: An Interpretive Description of South Asian Women and Health-Care Providers Living and Working in Southern Ontario, Canada. *Canadian Journal of Diabetes* 2021;45(2):144-54. doi: 10.1016/j.jcjd.2020.07.001
- 21. The Social Planning Council of Peel. An exploratory study of diabetes among South Asians in Peel. Peel, ON, 2015.
- 22. Greenhalgh T, Clinch M, Afsar N, et al. Socio-cultural influences on the behaviour of South Asian women with diabetes in pregnancy: qualitative study using a multi-level theoretical approach. *BMC Medicine* 2015;13(1):120. doi: 10.1186/s12916-015-0360-1
- 23. Region of Peel. 2016 Census Bulletin: Immigration and Ethnic Diversity 2017 [Available from: <u>https://www.peelregion.ca/planning-maps/CensusBulletins/2016-immigration-ethnic-diversity.pdf</u> accessed July 10 2022.
- 24. Best Start Resource Centre/ Government of Ontario. Prenatal Education Key Messages: Routine Prenatal Care 2016 [Available from: https://www.ontarioprenataleducation.ca/routine-prenatal-care/ accessed August 8 2022.
- 25. Tripkovic L, Muirhead NC, Hart KH, et al. The effects of a diet rich in inulin or wheat fibre on markers of cardiovascular disease in overweight male subjects. *Journal of Human Nutrition and Dietetics* 2015;28(5):476-85. doi: 10.1111/jhn.12251
- 26. Tricò D, Filice E, Baldi S, et al. Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients. *Diabetes & Metabolism* 2016;42(4):242-48. doi: 10.1016/j.diabet.2016.03.004
- 27. Numao S, Kawano H, Endo N, et al. Short-term low carbohydrate/high-fat diet intake increases postprandial plasma glucose and glucagon-like peptide-1 levels during an oral glucose tolerance test in healthy men. *Eur J Clin Nutr* 2012;66(8):926-31. doi: 10.1038/ejcn.2012.58

Protocol DESI-GDM

1 2	
2 3 4 5	28
6 7	29
8 9 10	30
11 12 13 14	31
15 16 17	32
18 19	33
20 21 22	34
23 24	35
25 26 27	36
28 29	37
30 31 22	38
32 33 34 35 36	39
37 38 39	40
40 41 42	41
43 44	42
45 46 47	43
48 49	44
50 51 52 53 54 55	45
56 57	
58 59 60	

8. Desai D, Kandasamy S, Limbachia J, et al. Studies to Improve Perinatal Health through Di	iet
and Lifestyle among South Asian Women Living in Canada: A Brief History and Futur	re
Research Directions. Nutrients 2021;13(9):2932. doi: 10.3390/nu13092932	


- 29. Feig DS, Berger H, Donovan L, et al. Diabetes and Pregnancy. *Canadian Journal of Diabetes* 2018;42:S255-S82. doi: 10.1016/j.jcjd.2017.10.038
- 30. Mijatovic-Vukas J, Capling L, Cheng S, et al. Associations of Diet and Physical Activity with Risk for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Nutrients* 2018;10(6) doi: 10.3390/nu10060698
- 31. Lee KW, Ching SM, Ramachandran V, et al. Prevalence and risk factors of gestational diabetes mellitus in Asia: a systematic review and meta-analysis. *BMC Pregnancy and Childbirth* 2018;18(1):494. doi: 10.1186/s12884-018-2131-4
- 32. Uhrich L. Family-centred maternity and newborn care: Canadian national guidelines. *International Journal of Childbirth Education* 2000;15(4):45.
- 33. Center for Disease Control and Prevention [CDC]. High Blood Pressure Symptoms and Causes 2021 [Available from: <u>https://www.cdc.gov/bloodpressure/about.htm</u> accessed December 6 2022.
- 34. HDP CPG Working Group, Association of Ontario Midwives. Hypertensive Disorders of Pregnancy. Clinical Practice Guideline no 15, 2012.
- 35. Statistics Canada. National Household Survey 2011, 2011.
- 36. Statistics Canada. The South Asian Community in Canada 2007 [Available from: <u>https://www150.statcan.gc.ca/n1/pub/89-621-x/89-621-x2007006-eng.htm#footnote2</u> accessed December 5 2022.
- 37. Kehler S, MacDonald T, Meuser A. Gestational Diabetes Mellitus: A review for midwives: Association of Ontario Midwives, n.d.
- 38. Lim SS, Noakes M, Norman RJ. Dietary effects on fertility treatment and pregnancy outcomes. Current Opinion in Endocrinology, Diabetes and Obesity 2007;14(6):465-69. doi: 10.1097/MED.0b013e3282f1cfc6
- 39. Kollmann M, Gaulhofer J, Lang U, et al. Placenta praevia: incidence, risk factors and outcome. *The Journal of Maternal-Fetal & Neonatal Medicine* 2016;29(9):1395-98. doi: 10.3109/14767058.2015.1049152
- 40. National Institute of Health [NIH]. What are some factors that make a pregnancy high risk? 2018 [Available from: <u>https://www.nichd.nih.gov/health/topics/high-risk/conditioninfo/factors#</u> accessed December 5 2022.
- 41. Efird J. Blocked Randomization with Randomly Selected Block Sizes. *International Journal* of Environmental Research and Public Health 2011;8(1) doi: 10.3390/ijerph8010015
- 42. Bandura A. Social foundations of thought and action. *Englewood Cliffs, NJ* 1986;1986(23-28)
- 43. Prochaska JO. Transtheoretical model of behavior change. *Encyclopedia of behavioral medicine* 2020:2266-70.
- 44. Sacks FM, Carey VJ, Anderson CAM, et al. Effects of High vs Low Glycemic Index of Dietary Carbohydrate on Cardiovascular Disease Risk Factors and Insulin Sensitivity: The OmniCarb Randomized Clinical Trial. JAMA 2014;312(23):2531-41. doi: 10.1001/jama.2014.16658
- 45. Paquette M, Medina Larqué AS, Weisnagel SJ, et al. Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: a parallel, double-

blind, controlled and randomised clinical trial. *British Journal of Nutrition* 2017;117(4):519-31. doi: 10.1017/S0007114517000393


- 46. Valsesia A, Saris WHM, Astrup A, et al. Distinct lipid profiles predict improved glycemic control in obese, nondiabetic patients after a low-caloric diet intervention: the Diet, Obesity and Genes randomized trial. *The American Journal of Clinical Nutrition* 2016;104(3):566-75. doi: 10.3945/ajcn.116.137646
- 47. Davenport MH, Ruchat S-M, Poitras VJ, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. *British Journal of Sports Medicine* 2018;52(21):1367-75. doi: 10.1136/bjsports-2018-099355
- 48. Davenport MH, Sobierajski F, Mottola MF, et al. Glucose responses to acute and chronic exercise during pregnancy: a systematic review and meta-analysis. *British Journal of Sports Medicine* 2018;52(21):1357-66. doi: 10.1136/bjsports-2018-099829
- 49. Patwardhan B. Bridging Ayurveda with evidence-based scientific approaches in medicine. *EPMA Journal* 2014;5(1):19. doi: 10.1186/1878-5085-5-19
- 50. Bhalerao S, Deshpande T, Thatte U. Prakriti (Ayurvedic concept of constitution) and variations in platelet aggregation. *BMC Complementary and Alternative Medicine* 2012;12(1):248. doi: 10.1186/1472-6882-12-248
- 51. Iqbal R, Anand S, Ounpuu S, et al. Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries. *Circulation* 2008;118(19):1929-37. doi: doi:10.1161/CIRCULATIONAHA.107.738716
- 52. Kapoor D, Iqbal R, Singh K, et al. Association of dietary patterns and dietary diversity with cardiometabolic disease risk factors among adults in South Asia: The CARRS study: HEC Press 2018.
- 53. Slapnicar C, Lear SA, Dehghan M, et al. Relationship of parental feeding practices and diet with children's diet among South Asians in Canada. *Appetite* 2022;173:105991. doi: 10.1016/j.appet.2022.105991
- 54. Martin LR, Petrie KJ. Understanding the Dimensions of Anti-Vaccination Attitudes: the Vaccination Attitudes Examination (VAX) Scale. Annals of Behavioral Medicine 2017;51(5):652-60. doi: 10.1007/s12160-017-9888-y
- 55. Thompson D, Berger H, Feig D, et al. Diabetes and Pregnancy. *Canadian Journal of Diabetes* 2013;37:S168-S83. doi: 10.1016/j.jcjd.2013.01.044
- 56. Anand SS, Vasudevan A, Gupta M, et al. Rationale and design of South Asian Birth Cohort (START): a Canada-India collaborative study. *BMC Public Health* 2013;13(1):79. doi: 10.1186/1471-2458-13-79
- 57. Mohan V, Mahalakshmi MM, Bhavadharini B, et al. Comparison of screening for gestational diabetes mellitus by oral glucose tolerance tests done in the non-fasting (random) and fasting states. *Acta Diabetologica* 2014;51(6):1007-13. doi: 10.1007/s00592-014-0660-5
- 58. Duran A, Sáenz S, Torrejón MJ, et al. Introduction of IADPSG Criteria for the Screening and Diagnosis of Gestational Diabetes Mellitus Results in Improved Pregnancy Outcomes at a Lower Cost in a Large Cohort of Pregnant Women: The St. Carlos Gestational Diabetes Study. *Diabetes Care* 2014;37(9):2442-50. doi: 10.2337/dc14-0179
- 59. Lapolla A, Dalfrà MG, Ragazzi E, et al. New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnancy outcome. *Diabetic Medicine* 2011;28(9):1074-77. doi: 10.1111/j.1464-5491.2011.03351.x

- 60. Mission JF, Ohno MS, Cheng YW, et al. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 2012;207(4):326.e1-26.e9. doi: 10.1016/j.ajog.2012.06.048 61. Allison DB, Paultre F, Maggio C, et al. The Use of Areas Under Curves in Diabetes Research. Diabetes Care 1995;18(2):245-50. doi: 10.2337/diacare.18.2.245 62. Sakaguchi K, Takeda K, Maeda M, et al. Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance. Diabetology International 2016;7(1):53-58. doi: 10.1007/s13340-015-0212-4 63. Samaan Z, Schulze KM, Middleton C, et al. South Asian Heart Risk Assessment (SAHARA): Randomized Controlled Trial Design and Pilot Study. JMIR Res Protoc 2013;2(2):e33. doi: 10.2196/resprot.2621 64. Zulyniak MA, de Souza RJ, Mente A, et al. A randomized controlled trial of the effects of a prudent diet on cardiovascular risk factors, gene expression, and DNA methylation - the Diet and Genetic Intervention (DIGEST) Pilot study. BMC Nutrition 2016;2(1):34. doi: 10.1186/s40795-016-0074-6 65. Thompson MD, Trask AJ. Developmental Origins of Cardiovascular Dysfunction-Doomed From Birth? Circulation Journal 2016; 80(4):818-20. doi: 10.1253/circi.CJ-16-0207 66. Donazar-Ezcurra M, López-del Burgo C, Bes-Rastrollo M. Primary prevention of gestational
 - diabetes mellitus through nutritional factors: a systematic review. *BMC Pregnancy and Childbirth* 2017;17(1):30. doi: 10.1186/s12884-016-1205-4
 67. Anand SS, Gupta MK, Schulze KM, et al. What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the
 - skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. *International Journal of Obesity* 2016;40(2):239-44. doi: 10.1038/ijo.2015.171
 - 68. Wicks P, Richards T, Denegri S, et al. Patients' roles and rights in research. *BMJ* 2018;362:k3193. doi: 10.1136/bmj.k3193
 - 69. Greenhalgh T, Hinton L, Finlay T, et al. Frameworks for supporting patient and public involvement in research: Systematic review and co-design pilot. *Health Expectations* 2019;22(4):785-801. doi: 10.1111/hex.12888
 - 70. Phelan S, Jelalian E, Coustan D, et al. Protocol for a randomized controlled trial of prepregnancy lifestyle intervention to reduce recurrence of gestational diabetes: Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional. *Trials* 2021;22(1):256. doi: 10.1186/s13063-021-05204-w
 - 71. Giannakou K, Evangelou E, Yiallouros P, et al. Risk factors for gestational diabetes: An umbrella review of meta-analyses of observational studies. *PLOS ONE* 2019;14(4):e0215372. doi: 10.1371/journal.pone.0215372
 - 72. Torloni MR, Betrán AP, Horta BL, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. *Obesity Reviews* 2009;10(2):194-203. doi: 10.1111/j.1467-789X.2008.00541.x

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Note: GP – general practitioner; Wgt – weight; Ht – height; BP – blood pressure; FFQ – food frequency questionnaire; OGTT – Oral glucose tolerance test




The area-under-the curve of the 75-g OGTT. This is calculated by the trapezoidal method using the fasting, 1-h, and 2-h glucose. The AUC of the time-blood glucose curve of the OGTT approximately equals the areas of two trapezoids as follows: (0 h blood glucose + 1 h blood glucose) $\times 1/2 + (1 \text{ h blood glucose} + 2 \text{ h blood glucose}) \times 1/2$, which equals the following: 1 h blood glucose + (0 h blood glucose + 2 h blood glucose)/2.

Fig 2. AUC calculation.



Page 34 of 38






Fig 3. PRISMA Flow Diagram exemplar

PIRIT 2013 Checkli ection/item dministrative info	ist: Reco Item No	Description	Addressed on
ection/item	Item	seig eig	Addressed on
			Addressed on
dministrative info			page number
	rmation	t Super text ar	
tle	1	م في في مع Descriptive title identifying the study design, population, interventions, and, if apple abye, trial acronym	1
rial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
rotocol version	3	Date and version identifier	N/A
unding	4	Sources and types of financial, material, and other support	23
Roles and	5a	Names, affiliations, and roles of protocol contributors	1&3
sponsibilities	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, managemers, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee endpoint adjudication committee, data management team, and other individuals or groups over seeing the trial, if applicable (see Item 21a for data monitoring committee)	20-21
ol	•	es and 5a consibilities 5b 5c	 Sa Names, affiliations, and roles of protocol contributors Sb Name and contact information for the trial sponsor Sc Role of study sponsor and funders, if any, in study design; collection, management, apalysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities Sd Composition, roles, and responsibilities of the coordinating centre, steering committee endpoint adjudication committee, data management team, and other individuals or groups over geeing the trial, if applicable (see Item 21a for data monitoring committee)

			BMJ Open BMJ Open-2023	Page 36 of 38
1 2	Introduction		ight, i	
3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, includine sugmary of relevant4-64-	
6 7		6b	Explanation for choice of comparators	
8 9	Objectives	7	Specific objectives or hypotheses6	
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factor single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, explorations)777	
14 15	Methods: Participar	nts, inte	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of by tries where data will7 be collected. Reference to where list of study sites can be obtained	
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and8888888	
22 23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including hoge and when they will be10 administered	_
23 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial parti المقطع (eg, drug doseN/A change in response to harms, participant request, or improving/worsening diseas ج	_
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for the state of t	_
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	
34 35 36 37 38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,16-17 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	_
39 40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for7&fig 1 participants. A schematic diagram is highly recommended (see Figure)	_
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

Page 37 of 38			BMJ Open Sp	
1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was betermined, including _ clinical and statistical assumptions supporting any sample size calculations	7-8
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	99
6 7	Methods: Assignm	ent of i	nterventions (for controlled trials)	
8 9	Allocation:		ses reición de la companya de la com La companya de la comp	
10 11 12 13 14	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random not be provided in a separate document that is unavailable to the sequence of a	9
15 16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequers is ally numbered,	9
20 21 22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who what assign participants to	9-10
23 24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome	9
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for the sealing a participant's	9-10
30 31 32	Methods: Data coll	ection,	management, and analysis	
33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9
38 39 40 41 42		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	13-16
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

			BMJ Open cop	Page
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_19-20
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where details of the statistical analysis plan can be found, if not in the protocol	_17-18
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_18-19
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as random egy analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_18-19
14 15	Methods: Monitorin	ng	t aded f	
16 17 18 19 20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and report	20
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have been been been been made interim	_19-20
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneous before adverse	19-20
28 29 30 31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process and the sponsor	N/A
32 33	Ethics and dissemi	nation	nologies.	
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) ap	2&19
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility creeria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial regiseries, journals, regulators)	19
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 39 of 38			BMJ Open Sp pg	
1 2	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and9 how (see Item 32)	-
3 4 5 6 7 8 9 10 11 12		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillaryN/A	-
	Confidentiality	27	How personal information about potential and enrolled participants will be collected and ared, and maintained19 in order to protect confidentiality before, during, and after the trial	-
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall transford each study site24-25	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contracted al agreements that25 limit such access for investigators	-
16 17 18	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trialN/A	-
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healtheare professionals,21-22 the public, and other relevant groups (eg, via publication, reporting in results data as s, or other data sharing arrangements), including any publication restrictions	
		31b	Authorship eligibility guidelines and any intended use of professional writers	
		31c	Plans, if any, for granting public access to the full protocol, participant-level datas	
	Appendices		tech 13	
	Informed consent materials	32	Model consent form and other related documentation given to participants and autority of sed surrogatesN/A	
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for generative molecularN/A analysis in the current trial and for future use in ancillary studies, if applicable	
37 38 39 40 41	Amendments to the p	orotocol	that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboratien for important clarification on the item should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons	ns.
42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	5

Study protocol: A culturally-tailored personalizeD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus--a randomized trial (DESI-GDM)

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-072353.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Feb-2023
Complete List of Authors:	Stennett, Rosain; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact Adamo, Kristi; University of Ottawa Anand, Sonia; McMaster University, Department of Medicine; Population Health Research Institute, Bajaj, Harpreet; LMC Healthcare Bangdiwala, Shrikant ; Population Health Research Institute Desai, Dipika; McMaster University Faculty of Health Sciences, Health Research Methods, Evidence & Impact ; Population Health Research Institute Gerstein, HC; McMaster University, Department of Medicine; Population Health Research Institute Kandasamy, Sujane; McMaster University Faculty of Health Sciences, Health Research Methods, Evidence & Impact Khan, Farah; Population Health Research Institute Lear, Scott; Population Health Research Institute McDonald, Sarah; McMaster University Faculty of Health Sciences, Department of Health Research Institute Ritvo, Paul; York University, Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact; McMaster University Faculty of Health Sciences, Department of Health Research Institute Ritvo, Paul; York University, Kinesiology and Health Science Rogge, Andrea; Population Health Research Institute Schulze, Karleen; Population Health Research Institute Schulze, Karleen; Population Health Research Institute Schulze, Karleen; Population Health Research Institute Scherifali, Diana; McMaster University Faculty of Health Sciences, Department of Health Research Institute Scherifali, Diana; McMaster University Faculty of Health Sciences, Department of Obstetrics & Gynecology Stearns, Jennifer; McMaster University Faculty of Health Sciences, Department of Obstetrics & Gynecology Stearns, Jennifer; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact; McMaster University, Farncombe Family Digestive Health Research Institute Wahi, Gita; McMaster University Faculty of Paelath Sciences, Department of Health Research Methods, Evidence, and Impact; McMaster Univ

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19 20	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
43 46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Primary Subject Heading :	Nutrition and metabolism
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetes in pregnancy < DIABETES & ENDOCRINOLOGY, NUTRITION & DIETETICS, PUBLIC HEALTH
	SCHOLAR ONE [™]
	Manuscripts
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

ur (ABES) . data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

Study protocol: A culturally-tailored personalizeD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus--a randomized trial (DESI-GDM)

Stennett, RN¹, Adamo, K², Anand, SS^{1,3}, Bajaj, H⁴, Bangdiwala, SI^{1,3}, Desai, D^{1,3}, Gerstein, HC^{3,5}, Kandasamy, S¹, Khan, F³, Lear, SA³, McDonald, SD^{1,3,6}, Poscai, T^{3†}, Ritvo, P⁷, Rogge, A³, Schulze, KM³, Sherifali, D^{1,3,8}, Stearns, JC^{6,9}, Wahi, G^{1,10}, Williams, NC⁵, Zulyniak, MA¹¹, de Souza, RJ^{1,3}

Affiliations

¹Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

² School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada

³Population Health Research Institute, Hamilton Health Sciences Corporation, Hamilton, ON, Canada

⁴LMC Healthcare, Brampton, Ontario, Canada

⁵Department of Medicine, McMaster University, Hamilton, Ontario, Canada

⁶Obstetrics & Gynecology, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

⁷Department of Psychology, York University, North York, Ontario, Canada

⁸School of Nursing, McMaster University, Hamilton, Ontario, Canada

⁹Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada

¹⁰ Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

¹¹School of Food Science and Nutrition, University of Leeds, Leeds, United Kingdom

[†] Affiliation at time of preparation of manuscript

*Corresponding author: Russell J. de Souza, desouzrj@mcmaster.ca

Protocol DESI-GDM

BMJ Open

2		
3 4	1	Abstract
5 6	2	Introduction: South Asians are more likely to develop gestational diabetes mellitus (GDM) than
7 8 9 10 11 12 13 14 15	3	White Europeans. Diet and lifestyle modifications may prevent GDM and reduce undesirable
	4	outcomes in both the mother and offspring. Our study seeks to evaluate the effectiveness and
	5	participant acceptability of a culturally-tailored, personalized nutrition intervention on the
	6	glucose area under the curve (AUC) after a 2-hour 75g oral glucose tolerance test (OGTT) in
16 17	7	pregnant women of South Asian ancestry with GDM risk factors.
18 19 20	8	Methods and Analysis: One hundred ninety pregnant South Asians with at least 2 of the
21 22	9	following GDM risk factors—pre-pregnancy body mass index (BMI) >23, age \geq 29, poor-quality
23 24	10	diet, family history of type 2 diabetes (T2DM) in a first-degree relative, or GDM in a previous
25 26 27	11	pregnancy will be enrolled during gestational week 12-18, and randomly assigned in a 1:1 ratio
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	12	to: 1) usual care, plus weekly text messages to encourage walking and paper handouts or 2) a
	13	personalized nutrition plan developed and delivered by a culturally-congruent dietitian and
	14	health coach; and FitBit® to track steps. The intervention lasts 6 – 16-weeks, depending on
	15	week-of-recruitment. The primary outcome is the glucose AUC from a 3-sample 75 g OGTT 24-
	16	28 weeks gestation. The secondary outcome is GDM diagnosis, based on Born-in-Bradford
	17	criteria (fasting glucose \geq 5.2 mmol/L, or 2-hour post-load \geq 7.2 mmol/L).
41 42 43	18	Ethics and Dissemination: The study has been approved by the Hamilton Integrated Research
44 45	19	Ethics Board (HiREB #10942). Findings will be disseminated among academics and policy
46 47	20	makers through scientific publications along with community orientated strategies.
48 49 50	21	Word count: 249
51 52	22	Trial Registration: ClinicalTrials.gov NCT03607799. Registered July 31, 2018
53 54	23	Key words: Gestational diabetes mellitus, South Asian, personalized nutrition intervention
55 56 57		
57 58 59		
60		For peer review only - http://bmiopen.hmi.com/site/about/guidelines.xhtml

Protocol DESI-GDM

Strengths and limitations of this study:

- The DESI GDM study intervention is informed by the findings of a previous qualitative study which assessed barriers and facilitators of lifestyle changes to prevent GDM, as well a birth cohort study completed in a similar population.
- This study utilizes an end user co-developed approach to intervention study which seeks • to improve participant engagement and buy-in.
 - The study is powered to detect a moderate treatment effect on the glycemic response to • the oral glucose tolerance test however, not GDM.

Page 4 of 39

Protected by copyright, including for uses related to text and

ur (ABES) . data mining, Al training, and similar technologies.

Protocol DESI-GDM

Introduction Gestational diabetes mellitus (GDM) is a condition in which a woman without existing diabetes develops high blood sugar levels during pregnancy.¹ Complications for the baby include neonatal hypoglycemia and intensive-care admission.² GDM is a strong risk factor for future type 2 diabetes (T2DM): up to 50% of women with GDM develop T2DM within 5 years of giving birth³⁴, and face up to seven-fold higher lifetime risk of T2DM compared with women who have a non-GDM pregnancy.³⁵ Additionally, GDM is associated with future atherosclerosis and cardiovascular disease (CVD) in the mother and increases the risk of T2DM in offspring up to eight-fold.5-8 South Asians (SA), whose ancestors are from India, Pakistan, Bangladesh, or Sri Lanka, are the largest non-white ethnic group in Canada, and are at high risk of T2DM and early CVD. GDM increases the risk of future T2DM and CVD. The development of GDM is influenced by several factors, notably ethnicity and diet. SA are two times more likely to develop GDM relative to white European women^{9 10}, and risk factors for future T2DM in the offspring including higher birthweight, more adipose tissue, and reduced insulin sensitivity, are more common in SA infants of mothers with GDM than infants born to mothers without GDM.⁹ Furthermore a low quality diet (diet higher in meat, meat dishes, processed meats, organ meats, poultry, fish, seafood, rice, fried foods, refined grains (breads and cereals), fast foods and eggs)

BMJ Open

during pregnancy increases one's odds of developing GDM (odds ratio [OR]: 1.62; 95% CI: 1.20
to 2.19).⁹ It is assumed that approximately 13% of GDM cases in SA could be prevented by a
healthy diet (population attributable risk [PAR]: 12.8%).⁹

Food-based interventions show the most potential for preventing GDM.¹¹⁻¹³ A network
 meta-analysis (21 randomized trials during pregnancy; n=1,865 women) ¹⁴ reported that diets

Protocol DESI-GDM

Page 5 of 31

57	with reduced glycemic load and/or increased fibre intake, compared to gestational weight gain
58	advice, improved fasting glucose levels. In another meta-analysis of randomized control trials,
59	diet modification alone led to the largest reduction in risk of excessive maternal weight gain and
60	(3 trials; n=409 women) reduced the incidence of GDM (relative risk [RR]: 0.68; 95% CI: 0.48
61	to 0.96), however the overall evidence rating was low to very low for the latter outcome ¹⁵ . There
62	is a need for more robust food-based intervention studies that consider additional factors in the
63	development of GDM in order to provide optimal prevention strategies for women at higher risk
64	of developing the condition.
65	Few randomized trials of the effect of diet and/or physical activity on incident GDM have
66	been conducted. One recent randomized trial conducted in Ireland (n=565) found that an exercise
67	and nutrition program delivered via smartphone did not reduce GDM in overweight and obese
68	women randomized at a mean gestational age of 15.3 weeks (RR: 1.1; 95% CI: 0.71 to 1.66) ¹⁶ .
69	However, this study aimed to modify only one aspect of diet, which was reducing the glycemic
70	index. A second trial conducted in Spain (n=1000) found that a Mediterranean dietary pattern
71	supplemented with extra virgin olive oil and pistachios, reduced the incidence of GDM (RR:
72	0.73; 95% CI: 0.56 to 0.95) compared with standard low-fat dietary advice ¹⁷ . A third trial,
73	Project SARAS in Mumbai, India ¹⁸ , was an unblinded, individually randomized controlled trial
74	of diet to prevent GDM in women living in slums. The intervention included a daily snack made
75	from leafy green vegetables, fruit, and milk for the treatment group, compared with low-
76	micronutrient vegetables (e.g., potato and onion) for the control group, on top of the usual diet.
77	Of 6,513 women, 35% became pregnant; of these, 89% reached a gestation of 28 wks., and 50%
78	(n=1,008) attended an OGTT. In total, 9.9% (n=100) developed GDM using the World Health
79	Organization's 1999 defintion. ¹⁹ Although there were many challenges of conducting this trial

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Protocol DESI-GDM

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

(i.e., 50% lost to follow-up), in an intention-to-treat (ITT) analysis, GDM was reduced in the
treatment group (7.3% compared with 12.4% in controls; OR: 0.56; 95% CI: 0.36, 0.86; P =
0.008). The reduction remained significant after adjusting for pre-pregnancy adiposity and fat or
weight gain during pregnancy.

In a qualitative interpretive descriptive study of barriers and facilitators to healthy eating encountered by pregnant and recently pregnant South Asian women and health care providers living and working in the Peel Region of Ontario, Canada²⁰, women voiced several facilitators to healthy eating such as: *i*) knowledge of culturally appropriate healthy foods; and *ii*) access to a health care provider able to provide resources and support in a timely fashion. Participants also identified barriers to healthy eating, including difficulty: i) changing long-held cultural diet practices; *ii*) adapting standard dietary advice to personal health beliefs; *iii*) navigating food choices at family gatherings; and *iv*) accommodating meal needs of others in the household. Women expressed a desire to learn more about healthy eating to prevent diabetes during pregnancy and were keen to use mobile health technology. Health care providers identified two major challenges to providing appropriate advice to members of this community: *i*) insufficient time for counselling; and *ii*) lack of familiarity with South Asian foods. These findings are consistent with other studies of sociocultural influences on behaviour in pregnancy in South Asian women. 21 22

98 These observations have led us to design and evaluate the effectiveness and participant 99 acceptability of a randomized controlled trial of a culturally-tailored, personalized nutrition 100 intervention, delivered by a health coach, on the glucose area under the curve (AUC) after a 2-101 hour 75-g oral glucose tolerance test (OGTT) to pregnant South Asian women at risk of GDM 102 living in Southern Ontario, Canada. The trial protocol follows the guidelines for protocol

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2		
- 3 4	103	development and reporting described by the Standard Protocol Items: Recommendations for
5 6	104	Interventional Trials (SPIRIT) 2013 statement (see Additional file 1).
7 8 9	105	Methods
9 10 11	106	Design: The study is a two-arm parallel RCT. The allocation ratio will be 1:1 to the intervention
12 13	107	or usual care (control) group. The study schema diagram illustrates the referral and screening
14 15 16 17	108	procedure (Figure 1).
17 18 19	109	Setting: The study will be conducted in Southern Ontario with the primary recruitment site being
20 21	110	the Regional Municipality of Peel, which consists of three municipalities to the west and
22 23 24	111	northwest of the city of Toronto: the cities of Mississauga and Brampton, and the town of
24 25 26	112	Caledon. More than half of the residents of the Region of Peel identify as South Asian. ²³ The
27 28 29 30	113	region has >800 family physicians and >60 obstetricians who see approximately 5,000 South
	114	Asian women/year in the second trimester of pregnancy. Expectant women routinely attend their
31 32 33	115	first visit between 12 - 18 weeks of pregnancy and then every four weeks until 30 weeks'
34 35	116	gestation; every two weeks from 32 to 36 weeks' gestation; and once a week from 37 weeks'
36 37 38	117	gestation until birth. ²⁴
39 40 41	118	Sample size: With 86 participants per group (total $n = 172$), the study will have 90% power to
42 43	119	detect at least a 15% between-group difference in AUC glucose, the primary outcome,
44 45 46	120	assuming 70% adherence to the intervention (i.e. goal setting, health coach contacts, food
40 47 48	121	tracking) and SD of AUC glucose = 173 mmol/min ⁹ . A change in glucose of at least this
49 50	122	magnitude has been observed in trials of similar design to test fibre supplements ²⁵ , high-protein
51 52	123	²⁶ , or high-fat diets ²⁷ . A 10% loss-to-follow up is assumed, which is low for dietary
53 54 55	124	interventions, however given the frequent expected contact with health care providers during
56 57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

Protocol DESI-GDM

BMJ Open

Page 8 of 31

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

125	pregnancy, the virtual nature of our intervention, and our pilot data, ²⁸ it is believed to be feasible.
126	The sample size has been inflated to 95 per group (total $n = 190$) to account for the expected high
127	lost-to-follow up. The study will have low power to detect a moderate treatment effect on the
128	secondary outcome of GDM (i.e., 20-30% between-treatment difference), and higher power to
129	detect very large treatment effects in GDM (i.e., 80% power to detect a 61% relative risk
130	reduction). The study will look to see if GDM incidence, measured as a dichotomous outcome, is
131	nominally improved.
132	Inclusion criteria: Singleton pregnant South Asian women will be enrolled between 12 – 18
133	weeks gestation. This timeframe avoids the early pregnancy window, when women are most
134	likely to experience nausea, and is past the highest period of risk for spontaneous abortion. In
135	addition to being South Asian, a high-risk ethnic group for GDM ²⁹ , participants will also need to
136	meet at least 2 GDM risk factors: age>299, low diet quality (assessed with a short diet screener) 9
137	³⁰ , family history of DM/GDM during a previous pregnancy ^{29 31} , or a pre-pregnancy BMI \geq 23. ⁹

Exclusion criteria: Expectant mothers with any of the following will be excluded from the study: a) pre-existing type 1 or type 2 diabetes²⁹; b) hypertension (\geq 140 mmHg systolic or \geq 90 mmHg diastolic) or on medication for the condition³²⁻³⁴; c) serious difficulty understanding health information in English, based on the screening conversation, that would preclude informed consent and participation (93% of Canadian South Asian women in the National Household Survey could conduct a conversation in one or both official languages (English and French) ^{35 36}; d) those unwilling or unable to modify their eating habits, based on a screening question; e) those at high risk of adverse pregnancy outcomes other than GDM (e.g., twins or higher-order multiples^{32 37}, use of fertility treatments³⁸, history of hypertension/pre-eclampsia,

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

1		
2 3 4	147	history ³⁴ of placenta previa ³⁹ or pre-term delivery ⁴⁰); or f) enrolment in another intervention
5 6 7	148	study that would compromise full participation in the DESI-GDM) trial.
8 9 10	149	Recruitment: Because of the COVID-19 pandemic, and the university research policies the
11 12	150	study recruitment was delayed but began in November 2021 and is expected to be completed
13 14	151	March 2024. The study team will provide study information to primary care physicians and
15 16 17 18	152	obstetricians who will identify and refer participants into the study.
19 20	153	Randomization and blinding: Women will be randomized 1:1 to intervention or contra
21 22	154	using a centralized integrated web response system (IWRS) at the Population Health Research
23 24 25	155	Institute (PHRI) in Hamilton, Ontario. A statistician will generate a randomization list using
26 27	156	permuted blocks algorithm with randomly chosen block sizes to ensure balance in numbers
28 29	157	avoid predictability. ⁴¹ The nature of the intervention precludes blinding of the participants to
30 31	158	treatment assignment, however, those providing the analysis of blood glucose levels for
32 33 34 35	159	assessing the primary and secondary outcomes will be blinded to treatment assignment.
36 37	160	At the baseline visit, the research assistant (RA) will confirm eligibility and obtain
38 39 40	161	consent, either in person, verbally via telephone or web conferencing, or electronically via
40 41 42	162	REDCap. These three options are believed to be flexible and responsive to participant
43 44	163	preference, and possible regulations regarding COVID-19 public health measures. After
45 46	164	confirming eligibility and the informed consent discussion, the RA will collect baseline
47 48 49	165	measures.
50 51 52 53	166	After collecting baseline physical measures, the study personnel completing the visit
54 55 56 57	167	activate the IWRS to randomly allocate participants to control or intervention in a concealed
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 9 of 31

Protocol DESI-GDM

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

fashion using a computer-generated random sequence. Those assigned to the intervention will be
assigned to a health coach, who will contact the participant for a baseline nutrition assessment,
and goal-setting session. Planned assessment visits take place at 3 time points regardless of the
study arm: 1) baseline 12 – 18 weeks gestation; 2) follow-up 24–28 weeks of gestation; and 3)
post-delivery – pregnancy and birth outcomes.

173 Intervention

In our intervention study which seeks to address behavioral changes, we used goal setting, behavioral contracting through bi-weekly checkups, and tailored health communication (text messaging). These strategies were drawn from the Social Cognitive Theory of behavioral changes⁴² and applied stages of change construct of the Transtheoretical Model⁴³. The activities used in the intervention are guided by the findings of 1) the START birth cohort study⁹, which identified diet as a key modifiable risk factor for GDM, and 2) a qualitative study of barriers and facilitators to healthy eating encountered by pregnant and recently pregnant South Asian women and health care providers living and working in Ontario²⁰.

Duration: Treatment/ intervention duration will be between 6 and 16 weeks, depending on the
 gestational age at enrollment. Effects of dietary intervention on glycemic endpoints are
 detectable in ≤6 week^{44 45}, and reach maximal effectiveness after 8-10 weeks (~2 months) of
 intervention⁴⁶. In-person or Zoom study visit contact will occur 2 times: once for the baseline
 visit and once for the OGTT. Between these visits, all participants receive weekly text messages,
 and intervention participants will also have bi-weekly telephone or video conferencing
 (Zoom/WhatsApp).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

		Protoc	col DESI-GDM	Page 11 of 31
	189	Treat	ment group: A personalized nutrition plan will be developed for each won	nan by a
	190	cultur	ally-congruent dietitian. Our dietary intervention will focus on:	
	191	i)	providing personalized food recommendations that consider a woman's of	eurrent dietary
)	191	ij	habits by identifying food choices and substitutions that will optimize the	-
-	193	ii)	providing dietary advice that is sensitive to religious belief/practice if de	
	194		participant (e.g., vegetarian foods maybe preferred by <i>Hindu</i> , <i>Buddhists</i> ,	-
,	195		while inclusion of meat may be more appropriate for <i>Sikhs</i> and <i>Christian</i>	
)	196		(e.g., Northern vs. Southern India, Sri Lanka, Bangladesh, Pakistan) culi	
	197		and	
-	198	iii)	involving the household meal preparer, if this is not the participant herse	lf, in the
, ,	199		coaching contacts; and use mobile health technology to reduce the amou	nt of in-office
,))	200		time a health care practitioner spends on dietary counselling. Additionall	y, participants
-	201		assigned to the intervention group will be given a Fitbit to track their step	os along with
-	202		encouragement to increase walking.	
,				
;	203	The h	ealth coach will co-design a plan with each participant that considers basel	ine dietary
)	204	intake	e, energy balance for recommended gestational weight gain, personal value	s, and
	205	prefer	rences, and set 2-4 "SMART" goals. Nutrition and behaviour change exper	ts have
-	206	develo	oped text messages that support 11 categories of nutrition goals (Table 1),	targeted to
,	207	addres	ss eating behaviours identified by participants in our qualitative study, desi	gned to optimize
)	208	energy	y balance for weight gain and improve dietary quality.	
-	209	Table	e 1. Categories of nutrition goals	

 Protocol DESI-GDM

1. Eating out healthy	2. Reduce indulgence in sweets/desserts
3. Controlling over-eating	4. Reduce intake of sugary beverages
5. Reducing high-fat, fried foods	6. Cooking meals at home more
7. Reducing highly refined carbohydrates	8. Improving meal planning
9. Encouraging mindful eating	10. Eating more fruits and vegetables
11. Increasing quality protein intake	

Both groups: Participants in both groups receive weekly text messages, aimed at increasing walking, as this was identified as a way to increase physical activity during pregnancy that was acceptable to South Asian women to undertake during pregnancy,²⁰ and is critical for glucose homeostasis during pregnancy.^{47 48} Both groups will be given resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy(paper handouts) plus additional materials adapted specifically for the South Asian community. Health care providers in Peel Region use these tools routinely (Diabetes Canada: https://bit.ly/2m8r2tT; or Heart & Stroke: https://bit.ly/2lDubl7).

219 Study Measurements and Schedule

220 Baseline assessment (for both intervention and control participants): At the baseline visit,

221 participants' physical measurement (height, weight, blood pressure, skinfold thickness and mid-

- 222 upper arm circumference), fasting urine and blood sample will be collected. Additionally, an
- ayurvedic assessment and 3 questionnaires (baseline instrument, INTERHEART Food
- Frequency Questionnaire (FFQ) and COVID-19 and vaccine questionnaire) will be administered.

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

The baseline instrument is researcher developed and has 4 sections: 1. Socio-demographics; 2.

Protocol DESI-GDM

Page 13 of 31

226	medical history; 3. obstetric history; and 4. lifestyle history.
227	The Ayurvedic "prakriti" assessment is a way of characterizing a population into set
228	subgroups, based on traditional Indian medicine called Ayurveda. This is a method of taking a
229	person-centered approach to health care49, based on phenotypic characteristics such as
230	appearance, mannerisms, etc. and is used for personalizing medicine and ways of healthy living
231	for individual. We will use the validated TNMC questionnaire from 2004.50 The decision to use
232	this tool was taken during the development of the protocol, through conversations with members
233	of the team and potential participants who practice Ayurveda. We may explore differences in the
234	primary outcome according to prakriti, however these are post-hoc, exploratory analyses only.
235	The INTERHEART FFQ (modified for use in pregnancy) is a semiquantitative food
236	frequency questionnaire (FFQ) that assesses intake of fruits and vegetables, and fast foods
237	consumption. The FFQ was adapted from the 19-item INTERHEART FFQ ⁵¹ , which has been
238	used in studies that included South Asians. ^{52 53}
239	The COVID-19 and vaccine questionnaire a short two-part, self-administered
240	questionnaire. We have decided to administer this because the COVID-19 pandemic has
241	impacted all aspects of day-to-day life, and its impact on our participants will help contextualize
242	our findings. The first part is the Vaccination Attitudes Examination (VAX) scale ⁵⁴ , a validated,
243	and reliable tool that assesses general vaccination attitudes across 4 domains: 1. Mistrust of
244	vaccine benefit; 2. Worries about unforeseen future events; 3. Concerns about commercial
245	profiteering; and 4. Preference for natural immunity. The second section comprises additional

questions about preferred types of vaccines, preferred location of receiving the vaccine, and

247 general attitudes/concerns about vaccines.

Page 15 of 39

Protocol DESI-GDM

Page 14 of 31

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES).

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text

Participants will be given an option to provide their health card number, which will
enable future linkage with administrative data sources from Ontario such as the Institute for
Clinical Evaluative Sciences (ICES) for potential health economic evaluation and for long-term
follow-up of the mother and her child.

BMJ Open

Weekly and Health Coach Visit: Participants in both control and intervention groups receive 1 text message every week up to the date of the OGTT with 1 of the 6 walking tips, sent by an automated outbound messaging system developed by MemoTXT (Toronto, ON). The intervention group only will also be sent weekly text messages to reinforce individual nutrition goals at times of day requested by the participant. Participants assigned to the intervention group will be given a Fitbit to track their steps; and will be requested to track food consumption in Bitesnap, a photo food journal app, for 2 weekdays and 1 weekend day bi-weekly (up to 8 assessments). Health coaches will be able to view both Fitbit and Bitesnap data via the Health Coaching Platform.

Coaching contacts to the intervention group will be made bi-weekly up to the date of their OGTT. These coaching calls will be recorded using an audio recording device. At each scheduled contact, intervention participants review agreed-upon diet goals, and assess, on a Likert scale, how often they were able to achieve the goals (ranging from "never" to "all of the time"); the coach will work with the participant to overcome barriers using our Brief Action Planning Guide. After each coaching call, participants and Health Coaches will complete a Visit Reflection questionnaire.

The central coordinator will review data regularly for completion, and *ad* hoc calls may be made to clarify items for either arm, but no counseling is provided to control group participants (see Table 2 for details).

Protocol DESI-GDM

Table 2. Schedule of study activities

Baseline Visit	Weekly	Health Coach Visits (bi- weekly)	OGTT Visit	Post-Birt Follow-u
X				
x				
x				
X				
x			X	
X				
			X	
X				
	X			
		X		
		X		
	X			
			X	
				X
	X X X	X X	X X X <td>X X X X</td>	X X X X

sample collection are repeated (this may be done virtually, or in-person) and a 75-g OGTT is

BMJ Open

Protocol DESI-GDM

Page 16 of 31

278	performed. Additional blood samples will be collected at 3-time points (0 hr, 1 hr and 2 hr)
279	during the OGTT (based on referral and participant willingness) and stored for future analysis.
280	In Peel, pregnant women usually undergo a 50-g glucose challenge at 24-28 weeks, with
281	a 1-h value \geq 7.8 mmol/L being an indication for a 75-g OGTT. ⁵⁵ Rather than this 2-step process,
282	we have chosen to administer the 75- g OGTT to all women because: 1. it was used to establish
283	South Asian-specific diagnostic criteria for GDM, and thus the study's outcomes will be directly
284	comparable ¹⁰ ; 2. it avoids the high false-negative rate of the 50-g Glucose Challenge Test (GCT)
285	among South Asians ^{56 57} ; 3. one-step screening has potential for long-term cost-saving ⁵⁸⁻⁶⁰ ; and
286	4. Diabetes Canada recognizes that the one-step strategy can identify a subset of women who
287	would not otherwise be identified as having GDM and who may benefit with regard to certain
288	perinatal outcomes ²⁹ . The study team will coordinate with the health care provider to ensure
289	participants receive the 75-g OGTT between 24-28 weeks, avoiding the two-step screen.
290	At the completion of their OGTT, each woman will be asked to complete the DESI-GDM
291	exit survey. This is a 9-item questionnaire based on previous tools created and used by the study
292	team. Responses to each question are provided using a 5-item Likert scale (Strongly Disagree
293	through Strongly Agree).
294	Postnatal Assessment: Study participants will be contacted after delivering their baby to self-
295	report the birth weight and length of their baby. Participants will also be asked to provide details
•••	

Study outcomes

of any complications during delivery.

The primary clinical outcome of this trial is the area under the glucose curve (AUC) of the 3-sample OGTT. A measure of glycemic response, glucose AUC is a continuous measure of the

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Protocol DESI-GDM

Page 17 of 31

response to a 75-g OGTT that accounts for variations in fasting plasma glucose levels between individuals. It is calculated by the trapezoidal method using the fasting, 1-hour, and 2-hour glucose⁶¹ (Figure 2). The AUC is superior to a single measure, i.e., fasting or 2-hour glucose only, which may not provide complete information regarding plasma glucose processing after a load.62

5 7	306	The secondary outcome is GDM, classified using the cut-offs derived in the Born-in-
3	307	Bradford (BiB) cohort, which were found to be associated with 75% higher risk of LGA or infant
) I	308	adiposity [infant birth weight >90th percentile for gestational age or adiposity (sum of skinfold
2 3	309	measurements >90th percentile for gestational age) in a study of 5,408 SA women]. These values
+ 5 5 7	310	are fasting glucose \geq 5.2 mmol/L, or 2-hour post-load \geq 7.2 mmol/L ¹⁰ . Current clinical cut-offs
3 9)	311	for the 75-g OGTT used to diagnose GDM in the general population as defined by the Diabetes
 <u>2</u>	312	Canada's clinical practice guidelines are: fasting glucose \geq 5.3 mmol/L, 1-hour \geq 10.6 mmol/L,
3 1 5 5	313	or 2-hour \geq 9.0 mmol/L. ²⁹ The study team will assess the sensitivity and specificity of the BiB
7 3	314	definition against the International Association of the Diabetes and Pregnancy Study Groups
,) 	315	(IASPSG) or World Health Organization (WHO) criteria (see Table 3 for diagnostic criteria).

Table 3. Diagnostic criteria for secondary outcome, gestational diabetes mellitus (GDM)

Threshold	Fasting	1-h	2-h
BiB	>=5.2	-	>=7.2
IADPSG	>=5.1	>=10.0	>=8.5
WHO	>=7.0	-	>=7.8
Diabetes Canada	>=5.3	>=10.6	>=9.0

Planned data analysis

Protocol DESI-GDM

as conduct process and acceptability assessments:

- a) **Primary clinical outcome:** The study will assess the main effect of the diet intervention $(\beta 1)$
- on the primary outcome of glucose AUC with a linear regression model with *intervention* as the
- main effect (a dummy variable, where 1=treatment; 0=control).
- b) Secondary clinical outcome: The study will assess the main effect of the diet intervention
- (β1) on the secondary outcome of GDM by fitting a logistic regression model with *intervention*
- as the main effect (a dummy variable, where 1=treatment; 0=control).
- Table 4 provides a summary of the planned analysis objectives, outcome, hypothesis and
- methods of analysis, and Figure 3 is our proposed CONSORT flow diagram.

Table 4. Analysis Plan: objectives, outcome, hypothesis, and methods of analysis

The study will asses	Ν			Page 18 of 31
The study will asses	ss the main effect of	the diet intervention	n (β 1) based on two outc	comes as well
s conduct process a	and acceptability ass	sessments:		
ı) Primary clinical	outcome: The study	y will assess the mai	in effect of the diet interv	vention (β1)
on the primary outco	ome of glucose AU	C with a linear regre	ession model with <i>interv</i>	ention as the
nain effect (a dumr	nv variable, where 1	l=treatment; 0=contr	rol).	
			nain effect of the diet int	ention as the ervention intervention
· -		-	regression model with	intervention
			-	
is the main effect (a	i dummy variable, w	where 1=treatment; 0)=control).	
Table 4 provides a s	summary of the plan	ned analysis objecti	ves, outcome, hypothesi	is and
ſable 4. Analysis F	'lan: objectives, ou	tcome, hypothesis,	and methods of analys	
Objective	Outcomes	Measurement	Criteria for success	Method of analysis
Primary clinical	Glycemic response to the 75-g oral glucose tolerance test	Area under the curve of glucose	Mean statistically significant reduction of 15% in the intervention arm	Linear regression*
Secondary clinical	Gestational diabetes diagnosed by 75- g oral glucose	Fasting glucose \geq 5.2 mmol/L, or 2-hour post 75-g load \geq 7.2	OR <0.9 = signal of benefit OR > 1.1 = signal of	Logistic regression* Descriptive statistic (proportion)
	tolerance test	mmol/L	harm	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Protocol DESI-GDM

Page 19 of 31

on an ongoing basis (e.g., adherence, unmet goals/targets). The study team will review qualitative and quantitative data to refine implementation processes. Acceptability will be explored using semi-structured exit interviews after the OGTT visit, which allow each participant to reflect on their experiences with the program and convey what they liked and disliked about the study, and if they would recommend the program to a friend, as we have in previous studies of similar design.63 64 e) Handling of missing outcome data: Missing outcome data (OGTT) will be handled via multiple imputation as a sensitivity analysis if we have >30% missing outcome data. f) Sensitivity analyses (for primary and secondary outcomes only): The study team anticipate possible variation in treatment effect according to time in study and by clinic site (if multiple clinics refer participants). Women will be enrolled in the study between weeks 12-18 of pregnancy. The outcome will be assessed at week 24-28 of pregnancy. Therefore, the length of time that each woman will receive the intervention may vary. The first sensitivity analysis will adjust the primary outcome for time in study (OGTT date minus enrolment date). The second sensitivity analysis, if there is multiple sites of enrolment, the study team will consider a random effect of study site. d) Interim data analysis: No interim data analysis is planned. **Ethical considerations** The study has been approved by the Hamilton Integrated Research Ethics Board (HiREB #10942), and the trial is registered with clinical trials.gov (NCT03607799). Participants will

355 provide written, verbal, or electronic informed consent. If providing verbal consent, participants

will be sent the full consent via email or paper mail, to read and refer to while being consented.

357 If providing electronic consent via Research Electronic Data Capture (REDCap), participants

Protocol DESI-GDM

will be sent a link that contains the full consent and will review the consent over telephone or
web-conferencing with study staff. The participant will select whether they agree to participate at
the bottom of the consent page. Participant data will be deidentified to protect confidentiality and
will only be reported and published in aggregate. Any modifications made to the study protocol
will be shared with HiREB as stipulated and we will follow their advice regarding

- 363 implementation and dissemination.
- 364 Data monitoring and management

Study Coordination and Management: The principal investigator will take responsibility for the oversight of the study. The coordinating centre for the trial will be Population Health Research Institute (PHRI) in Hamilton, ON. The coordinating centre, under the direction of the study statistician, will receive all data, and take process steps to reduce missing data. A junior project manager, along with a graduate student will oversee the of recruitment of participants and handle central trial coordination. At weekly meetings, the study will review recruitment, minor adverse events, study inventories, and review any expressed concerns by participants or the team. The steering committee will direct operational/process, nutrition, coaching, and statistical aspects of the trial.

Data and Safety Monitoring: For a previous pilot study, the study team had convened a Data
and Safety monitoring committee (DSMC), consisting of two internal medicine specialists (one
being an experienced endocrinologist), and a biostatistician. This committee advised that a
DSMC was not required for the pilot, voting for a safety officer, and disbanded. The committee
advised the same for this trial. Therefore, at pre-specified meeting times, the safety officer,
trained in internal medicine, will review data, noting any of the 8 minor (mother – induced

Protocol DESI-GDM

Page 21 of 31

labour, anemia, urinary tract infection, fall/injury/accident related to study, low mood or high blood pressure; child - premature labour (<36 weeks) or shoulder dystocia), or 6 major maternal events (hyperemesis gravidarum, caesarean section, pre-eclampsia, primary post-partum hemorrhage >500mL, miscarriage or maternal mortality.); or 2 major infant events (mortality – (fetal and neonatal) or stillbirth). The safety officer will determine whether they are related to study participation. To evaluate safety outcomes, maternal blood pressure at baseline and the OGTT follow-up visit will be measured, and notes of any pregnancy complications at coaching contacts.

The safety officer will review an interim data analysis, comparing a) mean AUC glucose; and b) GDM incidence between treatment and control (blinded) after the first 25 participants have completed their OGTT visit. Thereafter, the safety officer will review the data following each additional 50 participants. There is no early stopping rule for this study. The study will only collect data at baseline and the OGTT visit.

Patient and Public Involvement

The study included recently pregnant SA women living in Peel (ON), public health practitioners, and primary care providers that work with pregnant SA women in the development of our intervention through focus groups and semi-structured interviews. The co-investigators who work with the SA community and serve on guidelines committees have been closely involved with developing this research proposal. The study's physician collaborators will be involved in the recruitment progress, to help troubleshoot challenges, and refine intervention implementation strategies during the grant cycle.

Dissemination plans

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	Protocol DESI-GDM Page 22 of 31
403	The findings of the study will be important in guiding future evidence-based recommendations
404	and public health policies to manage gestational glycemia in pregnant women at risk of GDM.
405	Throughout the study, a strategy for integrated Knowledge Translation will be used to develop a
406	series of digital projects (short digital story-based videos) that capture: 1. participant experiences
407	that include key messages about successful approaches to healthy eating that women would like
408	to share with their communities; and 2. key study findings regarding effective dietary changes to
409	reduce risk of GDM, and public health messages tailored for researchers, practitioners, and
410	policy makers. A community event will be organized to share participant results with the group.
411	The study team involved community organizations that they have worked with over the past 10
412	years to engage the SA community and health care professionals. The study will disseminate its
413	findings among academics and policy makers using traditional methods including scientific
414	publications, and if indicated, guideline development. The study will collaborate with family
415	physicians, Region of Peel Public Health, and Diabetes Canada through talks and briefing reports
416	to disseminate to community partners and Health Canada, Diabetes Canada, Heart and Stroke,
417	Canadian Medical Association, as well as targeted communication. Peel Public Health supports
418	"scale-up" of individual interventions using population health methods that complement clinician
419	efforts, including mass media, social media, and text messaging campaigns. If the study
420	demonstrate that providing tailored, culturally specific dietary advice during pregnancy to SA
421	women is feasible and effective, the study foresee adapting the approach to other at-risk
422	populations, including White European, African Canadian, or First Nations communities.
423	
424	Discussion and implications

BMJ Open: first published as 10.1136/bmjopen-2023-072353 on 2 May 2023. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Protocol DESI-GDM

Page 23 of 31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
34 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
55

425	This study protocol describes the first RCT that examines the effect of a culturally tailored,
426	personalized nutrition intervention on gestational glycemia in South Asian women living in
427	Canada. In addition to proximal complications for the newborn, including life-threatening low
428	blood sugar (hypoglycemia) and intensive-care admission, GDM is a risk factor for future
429	atherosclerosis and cardiovascular disease (CVD) in the mother and childhood adiposity, type 2
430	diabetes, and cardiovascular disease in her offspring. ²⁸ Over the past two decades, studies have
431	shown that starting interventions as early as infancy and perhaps before - may be an especially
432	effective approach to maintaining lifelong heart health. ⁶⁵ This intervention in pregnancy, aimed
433	at reducing glycemia and its effect on the newborn infant, has great potential to "break the cycle"
434	of maternal hyperglycemia and excess infant adiposity and insulin resistance, and eventually
435	cardiovascular disease in both mother and baby.
436	Previous intervention studies that have sought to reduce the risk of GDM have reported
437	mixed results, perhaps due to population heterogeneity of the maternal metabolic profile,
438	inconsistent application of GDM diagnostic criteria, along with varied implementation. ^{11-13 66}
439	The DESI GDM study is unique because it is culturally tailored for South Asian pregnant
440	women living in Canada, and it builds upon a qualitative study of the barriers and facilitators of
441	lifestyle changes to prevent GDM ²⁰ , as well a birth cohort study completed in a similar
442	population. ⁶⁷ Such culturally tailored and participant/end user co-developed approaches to
443	intervention studies improve engagement, by adding relevance to the intervention for
444	participants.68 69 By involving the members of the community likely to benefit from the
445	intervention in the design of the study through previous and ongoing work, the DESI-GDM
446	intervention is tailored to the needs and challenges of participants and is feasible. The study

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

BMJ Open

 447 team's connections with family physicians help encourage high rates of recruitment and 448 engagement as well as transferability and scale-up, as appropriate, of study results. 449 A limitation of the study is that participants in our study will be exposed to the 9 10 450 intervention only after becoming pregnant. Some researchers have posited that GDM pre 	timized"
 6 448 engagement as well as transferability and scale-up, as appropriate, of study results. 7 8 449 A limitation of the study is that participants in our study will be exposed to the 9 10 450 intervention only after becoming pregnant. Some researchers have posited that GDM pre 	timized"
 A limitation of the study is that participants in our study will be exposed to the intervention only after becoming pregnant. Some researchers have posited that GDM pre 	timized"
10 450 intervention only after becoming pregnant. Some researchers have posited that GDM pre	timized"
12_{13} 451 measures are most effective prior to pregnancy so that modifiable risk factors can be "op	ong 61
14 15 452 prior to pregnancy. ⁷⁰ However, an umbrella review by Giannakou, et al. ⁷¹ found that amo	
 16 17 453 risk factors for GDM, pre-pregnancy BMI was associated with increased risk of GDM, a 18 	ind the
 authors assessed the level of evidence to be "highly suggestive". Furthermore, a prevalen 	ce
21 22 455 meta-analysis of 70 studies involving 671 945 women found that every 1-unit increase in	pre-
 23 24 456 pregnancy BMI increased the prevalence of GDM by 0.92% (95% CI: 0.73 to 1.10).⁷² 25 	
The study is unique in that it is designed to deliver and test the uptake of a dietary The study is unique in that it is designed to deliver and test the uptake of a dietary	7
$\frac{28}{29}$ 458 intervention to reduce gestational dysglycemia in a high-risk population in Canada. This	
 intervention in pregnancy, aimed at reducing dysglycemia, has great potential to "break t 32 	he
 460 cycle" of maternal gestational dysglycemia and excess infant adiposity and insulin resistant 34 	ance,
$^{35}_{36}$ 461 and eventual CVD and T2DM, both of which are complications of GDM in both mother	and
37 38 462 baby.	
39 40 463 41	
42 43 464 Acknowledgements	
44 45 465 None.	
 46 47 466 Contributorship statement 48 	
⁴⁹ 467 RNS drafted the manuscript, RJdS, KA, SSA, HB, SIB, HCG, SK, SAL, SDM, PR, DS,	MAZ
 and GW conceived and designed the study. RJdS, HB, SIB, DD, FK, TP, AR, KMS, DS, 	JCS,
 52 53 469 NCW and MAZ participated in the development of the protocol and data acquisition met 54 	hods.
55 56 57	
58	
59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

participated in the design of the visits. All authors read and approved the final manuscript.

Funding Statement

Protocol DESI-GDM

This study is funded by The Canadian Institutes of Health Research (CIHR) application # 426250 (Project Grant), with additional support from the Population Health Research Institute

(PHRI) - Digital Health Initiative and Hamilton Health Sciences (HHS) - New Investigator Fund.

Competing interests

RJ de Souza has served as an external resource person to the World Health Organization's Nutrition Guidelines Advisory Group on *trans* fats, saturated fats, and polyunsaturated fats. The WHO paid for his travel and accommodation to attend meetings from 2012-2017 to present and discuss this work. He has presented updates of this work to the WHO in 2022. He has also done contract research for the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism, and Diabetes, Health Canada, and the World Health Organization for which he received remuneration. He has received speaker's fees from the University of Toronto, and McMaster Children's Hospital. He has held grants from the Canadian Institutes of Health Research, Canadian Foundation for Dietetic Research, Population Health Research Institute, and Hamilton Health Sciences Corporation as a principal investigator, and is a co-investigator on several funded team grants from the Canadian Institutes of Health Research. He has served as an independent director of the Helderleigh Foundation (Canada). He serves as a member of the Nutrition Science Advisory Committee to Health Canada (Government of Canada), and a coopted member of the Scientific Advisory Committee on Nutrition (SACN) Subgroup on the Framework for the Evaluation of Evidence (Public Health England). S Kandasamy received a CIHR video talks Prize for the Knowledge Translation (KT) video created for the South Asian Grandmothers Qualitative Substudy. She was also funded by a CIHR Vanier Doctoral scholarship to develop and evaluate the SMART START KT tools. Gita Wahi has held grants from the Canadian Institutes of Health Research, and she is currently the recipient of a Research Early Career Award from Hamilton Health Sciences Foundation. P Ritvo is currently funded by the Canadian Institutes of Health (CIHR) (2021–2025). He coordinates research with NexJ Health, Inc., which provides a software platform to convey the psychosocial and psychiatric programming he develops and assesses. Ritvo receives no personal compensations for studies coordinated with NexJ but does receive free-of-charge platform support. All other authors declare no conflicts of interest.

Availability of data and materials

The principal investigator Russell de Souza will have access to the final trial data set. Any data required to support the protocol can be supplied on request.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		Protocol DESI-GDM Page 26 of 31
2 3 4 5	507 508	The study has been approved by the Hamilton Integrated Research Ethics Board (HiREB #10942).
6	509	
7 8	203	
9 10		
11		
12 13		
14 15		
16 17		
18		
19 20		
21 22		
23		
24 25		
26 27		
28		
29 30		
31 32		
33 34		
35		
36 37		
38 39		
40		
41 42		
43 44		
45 46		
47		
48 49		
50 51		
52		
53 54		
55 56		
57		
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 28 of 39

2		
3	510	References
4	511	
5	512	1. National Institute of Diabetes and Digestive and Kidney Diseases. Gestational diabetes 2017 [updated
6	513	May 1, 2017. Available from: https://www.niddk.nih.gov/health-
7	514	information/diabetes/overview/what-is-diabetes/gestational accessed 5 March 2018.
8	515	2. Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse
9		pregnancy outcomes. <i>N Engl J Med</i> 2008;358(19):1991-2002. doi: 10.1056/NEJMoa0707943
10	516	3. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from
11	517	
12	518	precenception to the postnatal period London, UK2018 [Available from:
13	519	https://www.nice.org.uk/guidance/ng3/chapter/2-research-recommendations#postnatal-treatment-
14 15	520	for-women-diagnosed-with-gestational-diabetes accessed 5 March 2018.
15 16	521	4. Lee AJ, Hiscock RJ, Wein P, et al. Gestational diabetes mellitus: clinical predictors and long-term risk
16 17	522	of developing type 2 diabetes: a retrospective cohort study using survival analysis. <i>Diabetes Care</i>
18	523	2007;30(4):878-83. doi: 10.2337/dc06-1816 [published Online First: 2007/03/30]
19	524	5. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a
20	525	systematic review and meta-analysis. <i>Lancet</i> 2009;373(9677):1773-9. doi: 10.1016/S0140-
20	526	6736(09)60731-5
22	527	6. Gunderson EP, Chiang V, Pletcher MJ, et al. History of gestational diabetes mellitus and future risk of
23	528	atherosclerosis in mid-life: the Coronary Artery Risk Development in Young Adults study.
24	529	Journal of the American Heart Association 2014;3(2):e000490. doi: 10.1161/JAHA.113.000490
25	530	7. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in
26	531	adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of
27	532	intrauterine hyperglycemia. Diabetes Care 2008;31(2):340-6. doi: 10.2337/dc07-1596
28	533	8. Archambault C, Arel R, Filion KB. Gestational diabetes and risk of cardiovascular disease: a scoping
29	534	review. Open Med 2014;8(1):e1-9. [published Online First: 2014/07/11]
30	535	9. Anand SS, Gupta M, Teo KK, et al. Causes and consequences of gestational diabetes in South Asians
31	536	living in Canada: results from a prospective cohort study. CMAJ open 2017;5(3):E604. doi:
32	537	10.9778/cmajo.20170027
33	538	10. Farrar D, Fairley L, Santorelli G, et al. Association between hyperglycaemia and adverse perinatal
34	539	outcomes in south Asian and white British women: analysis of data from the Born in Bradford
35	540	cohort. The Lancet Diabetes & Endocrinology 2015;3(10):795-804. doi: 10.1016/S2213-
36	541	8587(15)00255-7
37	542	11. Madhuvrata P, Govinden G, Bustani R, et al. Prevention of gestational diabetes in pregnant women
38	543	with risk factors for gestational diabetes: a systematic review and meta-analysis of randomised
39	544	trials. Obstet Med 2015;8(2):68-85. doi: 10.1177/1753495X15576673
40	545	12. Rogozińska E, Chamillard M, Hitman GA, et al. Nutritional Manipulation for the Primary Prevention
41 42	546	of Gestational Diabetes Mellitus: A Meta-Analysis of Randomised Studies. PLOS ONE
42 43	547	2015;10(2):e0115526. doi: 10.1371/journal.pone.0115526
43 44	548	13. Song C, Li J, Leng J, et al. Lifestyle intervention can reduce the risk of gestational diabetes: a meta-
44	549	analysis of randomized controlled trials. Obesity Reviews 2016;17(10):960-69. doi:
46	550	10.1111/obr.12442
47	551	14. Ha V, Bonner AJ, Jadoo JK, et al. The effects of various diets on glycemic outcomes during
48	552	pregnancy: A systematic review and network meta-analysis. PLOS ONE 2017;12(8):e0182095.
49	553	doi: 10.1371/journal.pone.0182095
50	554	15. Thangaratinam S, Rogozińska E, Jolly K, et al. Effects of interventions in pregnancy on maternal
51	555	weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ 2012;344:e2088. doi:
52	556	10.1136/bmj.e2088
53	557	16. Kennelly MA, Ainscough K, Lindsay KL, et al. Pregnancy Exercise and Nutrition With Smartphone
54	558	Application Support: A Randomized Controlled Trial. Obstetrics & Gynecology 2018;131(5) doi:
55	559	10.1097/AOG.0000000002582
56		
57		
58		

Protocol DESI-GDM

2		
3	560	17. Assaf-Balut C, García de la Torre N, Durán A, et al. A Mediterranean diet with additional extra virgin
4	561	olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): A
5	562	randomized controlled trial: The St. Carlos GDM prevention study. PLOS ONE
6	563	2017;12(10):e0185873. doi: 10.1371/journal.pone.0185873
7	564	18. Sahariah SA, Potdar RD, Gandhi M, et al. A Daily Snack Containing Leafy Green Vegetables, Fruit,
8	565	and Milk before and during Pregnancy Prevents Gestational Diabetes in a Randomized,
9	566	Controlled Trial in Mumbai, India. <i>The Journal of nutrition</i> 2016;146(7):1453S-60S. doi:
10	567	10.3945/jn.115.223461
11 12	568	19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its
12	569	complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes
13 14	570	mellitus. In: World Health Organization, ed. Geneva, SUI, , 1999.
15	571	20. Kandasamy S, Nguyen L, Desai D, et al. Barriers to, and Facilitators of, Lifestyle Changes to Prevent
16	572	Gestational Diabetes: An Interpretive Description of South Asian Women and Health-Care
17	573	Providers Living and Working in Southern Ontario, Canada. Canadian Journal of Diabetes
18	574	2021;45(2):144-54. doi: 10.1016/j.jcjd.2020.07.001
19	575	21. The Social Planning Council of Peel. An exploratory study of diabetes among South Asians in Peel.
20	576	Peel, ON, 2015.
21	577	22. Greenhalgh T, Clinch M, Afsar N, et al. Socio-cultural influences on the behaviour of South Asian
22	578	women with diabetes in pregnancy: qualitative study using a multi-level theoretical approach.
23	579	<i>BMC Medicine</i> 2015;13(1):120. doi: 10.1186/s12916-015-0360-1
24	580	23. Region of Peel. 2016 Census Bulletin: Immigration and Ethnic Diversity 2017 [Available from:
25	581	https://www.peelregion.ca/planning-maps/CensusBulletins/2016-immigration-ethnic-
26	582	diversity.pdf accessed July 10 2022.
27	583	24. Best Start Resource Centre/ Government of Ontario. Prenatal Education Key Messages: Routine
28	584	Prenatal Care 2016 [Available from: https://www.ontarioprenataleducation.ca/routine-prenatal-
29	585	care/ accessed August 8 2022.
30	586	25. Tripkovic L, Muirhead NC, Hart KH, et al. The effects of a diet rich in inulin or wheat fibre on
31 22	587	markers of cardiovascular disease in overweight male subjects. Journal of Human Nutrition and
32 33	588	Dietetics 2015;28(5):476-85. doi: 10.1111/jhn.12251
33 34	589	26. Tricò D, Filice E, Baldi S, et al. Sustained effects of a protein and lipid preload on glucose tolerance
35	590	in type 2 diabetes patients. <i>Diabetes & Metabolism</i> 2016;42(4):242-48. doi:
36	591	10.1016/j.diabet.2016.03.004
37	592	27. Numao S, Kawano H, Endo N, et al. Short-term low carbohydrate/high-fat diet intake increases
38	593	postprandial plasma glucose and glucagon-like peptide-1 levels during an oral glucose tolerance
39	594	test in healthy men. <i>Eur J Clin Nutr</i> 2012;66(8):926-31. doi: 10.1038/ejcn.2012.58
40	595	28. Desai D, Kandasamy S, Limbachia J, et al. Studies to Improve Perinatal Health through Diet and
41	596	Lifestyle among South Asian Women Living in Canada: A Brief History and Future Research
42	597	Directions. <i>Nutrients</i> 2021;13(9):2932. doi: 10.3390/nu13092932
43	598	29. Feig DS, Berger H, Donovan L, et al. Diabetes and Pregnancy. <i>Canadian Journal of Diabetes</i>
44	599	2018;42:S255-S82. doi: 10.1016/j.jcjd.2017.10.038
45	600	30. Mijatovic-Vukas J, Capling L, Cheng S, et al. Associations of Diet and Physical Activity with Risk
46	601	for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 2018;10(6)
47	602	doi: 10.3390/nu10060698
48	603	31. Lee KW, Ching SM, Ramachandran V, et al. Prevalence and risk factors of gestational diabetes
49 50	604	mellitus in Asia: a systematic review and meta-analysis. <i>BMC Pregnancy and Childbirth</i>
50 51	605	2018;18(1):494. doi: 10.1186/s12884-018-2131-4
52	606	32. Uhrich L. Family-centred maternity and newborn care: Canadian national guidelines. <i>International</i>
53	607	Journal of Childbirth Education 2000;15(4):45.
55 54	608	33. Center for Disease Control and Prevention [CDC]. High Blood Pressure Symptoms and Causes 2021
55	609	[Available from: https://www.cdc.gov/bloodpressure/about.htm accessed December 6 2022.
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

1

Page 30 of 39


2			
3	610	34.	HDP CPG Working Group, Association of Ontario Midwives. Hypertensive Disorders of Pregnancy.
4	611		Clinical Practice Guideline no 15, 2012.
5 6	612	35.	Statistics Canada. National Household Survey 2011, 2011.
6	613		Statistics Canada. The South Asian Community in Canada 2007 [Available from:
7	614		https://www150.statcan.gc.ca/n1/pub/89-621-x/89-621-x2007006-eng.htm#footnote2 accessed
8	615		December 5 2022.
9	616	37.	Kehler S, MacDonald T, Meuser A. Gestational Diabetes Mellitus: A review for midwives:
10 11	617		Association of Ontario Midwives, n.d.
12	618	38.	Lim SS, Noakes M, Norman RJ. Dietary effects on fertility treatment and pregnancy outcomes.
12	619		Current Opinion in Endocrinology, Diabetes and Obesity 2007;14(6):465-69. doi:
14	620		10.1097/MED.0b013e3282f1cfc6
15	621	39.	Kollmann M, Gaulhofer J, Lang U, et al. Placenta praevia: incidence, risk factors and outcome. The
16	622		Journal of Maternal-Fetal & Neonatal Medicine 2016;29(9):1395-98. doi:
17	623		10.3109/14767058.2015.1049152
18	624	40.	National Institute of Health [NIH]. What are some factors that make a pregnancy high risk? 2018
19	625		[Available from: https://www.nichd.nih.gov/health/topics/high-risk/conditioninfo/factors#
20	626		accessed December 5 2022.
21	627	41.	Efird J. Blocked Randomization with Randomly Selected Block Sizes. International Journal of
22	628		Environmental Research and Public Health 2011;8(1) doi: 10.3390/ijerph8010015
23	629	42.	Bandura A. Social foundations of thought and action. <i>Englewood Cliffs, NJ</i> 1986;1986(23-28)
24	630		Prochaska JO. Transtheoretical model of behavior change. Encyclopedia of behavioral medicine
25	631		2020:2266-70.
26	632	44.	Sacks FM, Carey VJ, Anderson CAM, et al. Effects of High vs Low Glycemic Index of Dietary
27	633		Carbohydrate on Cardiovascular Disease Risk Factors and Insulin Sensitivity: The OmniCarb
28	634		Randomized Clinical Trial. JAMA 2014;312(23):2531-41. doi: 10.1001/jama.2014.16658
29	635	45.	Paquette M, Medina Larqué AS, Weisnagel SJ, et al. Strawberry and cranberry polyphenols improve
30 31	636		insulin sensitivity in insulin-resistant, non-diabetic adults: a parallel, double-blind, controlled and
32	637		randomised clinical trial. British Journal of Nutrition 2017;117(4):519-31. doi:
32 33	638		10.1017/S0007114517000393
34	639	46	Valsesia A, Saris WHM, Astrup A, et al. Distinct lipid profiles predict improved glycemic control in
35	640		obese, nondiabetic patients after a low-caloric diet intervention: the Diet, Obesity and Genes
36	641		randomized trial. The American Journal of Clinical Nutrition 2016;104(3):566-75. doi:
37	642		10.3945/ajcn.116.137646
38	643	47.	Davenport MH, Ruchat S-M, Poitras VJ, et al. Prenatal exercise for the prevention of gestational
39	644		diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-
40	645		analysis. British Journal of Sports Medicine 2018;52(21):1367-75. doi: 10.1136/bjsports-2018-
41	646		099355
42	647	48.	Davenport MH, Sobierajski F, Mottola MF, et al. Glucose responses to acute and chronic exercise
43	648		during pregnancy: a systematic review and meta-analysis. British Journal of Sports Medicine
44	649		2018;52(21):1357-66. doi: 10.1136/bjsports-2018-099829
45	650	49.	Patwardhan B. Bridging Ayurveda with evidence-based scientific approaches in medicine. <i>EPMA</i>
46	651		Journal 2014;5(1):19. doi: 10.1186/1878-5085-5-19
47	652	50.	Bhalerao S, Deshpande T, Thatte U. Prakriti (Ayurvedic concept of constitution) and variations in
48	653		platelet aggregation. <i>BMC Complementary and Alternative Medicine</i> 2012;12(1):248. doi:
49	654		10.1186/1472-6882-12-248
50 51	655	51.	Iqbal R, Anand S, Ounpuu S, et al. Dietary Patterns and the Risk of Acute Myocardial Infarction in 52
52	656		Countries. <i>Circulation</i> 2008;118(19):1929-37. doi:
52 53	657		doi:10.1161/CIRCULATIONAHA.107.738716
55 54	658	52	Kapoor D, Iqbal R, Singh K, et al. Association of dietary patterns and dietary diversity with
55	659		cardiometabolic disease risk factors among adults in South Asia: The CARRS study: HEC Press
56	660		2018.
57			
58			
59			

Protocol DESI-GDM


2		
3	661	53. Slapnicar C, Lear SA, Dehghan M, et al. Relationship of parental feeding practices and diet with
4	662	children's diet among South Asians in Canada. Appetite 2022;173:105991. doi:
5	663	10.1016/j.appet.2022.105991
6	664	54. Martin LR, Petrie KJ. Understanding the Dimensions of Anti-Vaccination Attitudes: the Vaccination
7	665	Attitudes Examination (VAX) Scale. Annals of Behavioral Medicine 2017;51(5):652-60. doi:
8	666	10.1007/s12160-017-9888-y
9	667	55. Thompson D, Berger H, Feig D, et al. Diabetes and Pregnancy. Canadian Journal of Diabetes
10 11	668	2013;37:S168-S83. doi: 10.1016/j.jcjd.2013.01.044
12	669	56. Anand SS, Vasudevan A, Gupta M, et al. Rationale and design of South Asian Birth Cohort
13	670	(START): a Canada-India collaborative study. BMC Public Health 2013;13(1):79. doi:
14	671	10.1186/1471-2458-13-79
15	672	57. Mohan V, Mahalakshmi MM, Bhavadharini B, et al. Comparison of screening for gestational diabetes
16	673	mellitus by oral glucose tolerance tests done in the non-fasting (random) and fasting states. Acta
17	674	Diabetologica 2014;51(6):1007-13. doi: 10.1007/s00592-014-0660-5
18	675	58. Duran A, Sáenz S, Torrejón MJ, et al. Introduction of IADPSG Criteria for the Screening and
19	676	Diagnosis of Gestational Diabetes Mellitus Results in Improved Pregnancy Outcomes at a Lower
20	677	Cost in a Large Cohort of Pregnant Women: The St. Carlos Gestational Diabetes Study. Diabetes
21	678	Care 2014;37(9):2442-50. doi: 10.2337/dc14-0179
22	679	59. Lapolla A, Dalfrà MG, Ragazzi E, et al. New International Association of the Diabetes and Pregnancy
23	680	Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with
24	681	former criteria: a retrospective study on pregnancy outcome. Diabetic Medicine 2011;28(9):1074-
25	682	77. doi: 10.1111/j.1464-5491.2011.03351.x
26	683	60. Mission JF, Ohno MS, Cheng YW, et al. Gestational diabetes screening with the new IADPSG
27	684	guidelines: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology
28	685	2012;207(4):326.e1-26.e9. doi: 10.1016/j.ajog.2012.06.048
29 30	686	61. Allison DB, Paultre F, Maggio C, et al. The Use of Areas Under Curves in Diabetes Research.
30 31	687	Diabetes Care 1995;18(2):245-50. doi: 10.2337/diacare.18.2.245
32	688	62. Sakaguchi K, Takeda K, Maeda M, et al. Glucose area under the curve during oral glucose tolerance
33	689	test as an index of glucose intolerance. Diabetology International 2016;7(1):53-58. doi:
34	690	10.1007/s13340-015-0212-4
35	691	63. Samaan Z, Schulze KM, Middleton C, et al. South Asian Heart Risk Assessment (SAHARA):
36	692	Randomized Controlled Trial Design and Pilot Study. JMIR Res Protoc 2013;2(2):e33. doi:
37	693	10.2196/resprot.2621
38	694	64. Zulyniak MA, de Souza RJ, Mente A, et al. A randomized controlled trial of the effects of a prudent
39	695	diet on cardiovascular risk factors, gene expression, and DNA methylation - the Diet and Genetic
40	696	Intervention (DIGEST) Pilot study. BMC Nutrition 2016;2(1):34. doi: 10.1186/s40795-016-0074-
41	697	6
42	698	65. Thompson MD, Trask AJ. Developmental Origins of Cardiovascular Dysfunction–Doomed From
43	699	Birth? Circulation Journal 2016; 80(4):818-20. doi: 10.1253/circj.CJ-16-0207
44	700	66. Donazar-Ezcurra M, López-del Burgo C, Bes-Rastrollo M. Primary prevention of gestational diabetes
45	701	mellitus through nutritional factors: a systematic review. BMC Pregnancy and Childbirth
46	702	2017;17(1):30. doi: 10.1186/s12884-016-1205-4
47 49	703	67. Anand SS, Gupta MK, Schulze KM, et al. What accounts for ethnic differences in newborn skinfold
48 49	704	thickness comparing South Asians and White Caucasians? Findings from the START and
50	705	FAMILY Birth Cohorts. International Journal of Obesity 2016;40(2):239-44. doi:
51	706	10.1038/ijo.2015.171
52	707	68. Wicks P, Richards T, Denegri S, et al. Patients' roles and rights in research. <i>BMJ</i> 2018;362:k3193.
53	708	doi: 10.1136/bmj.k3193
54	709	69. Greenhalgh T, Hinton L, Finlay T, et al. Frameworks for supporting patient and public involvement in
55	710	research: Systematic review and co-design pilot. Health Expectations 2019;22(4):785-801. doi:
56	711	10.1111/hex.12888
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protocol DESI-GDM

1		
2 3 4 5	712 713	70. Phelan S, Jelalian E, Coustan D, et al. Protocol for a randomized controlled trial of pre-pregnancy lifestyle intervention to reduce recurrence of gestational diabetes: Gestational Diabetes
5 6	714	Prevention/Prevención de la Diabetes Gestacional. <i>Trials</i> 2021;22(1):256. doi: 10.1186/s13063-
7	715 716	021-05204-w 71. Giannakou K, Evangelou E, Yiallouros P, et al. Risk factors for gestational diabetes: An umbrella
8 9	717	review of meta-analyses of observational studies. <i>PLOS ONE</i> 2019;14(4):e0215372. doi:
9 10	718	10.1371/journal.pone.0215372
11	719 720	72. Torloni MR, Betrán AP, Horta BL, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. <i>Obesity Reviews</i> 2009;10(2):194-203. doi:
12 13	720	10.1111/j.1467-789X.2008.00541.x
14	722	
15	723	
16 17	724	
18	725 726	
19 20	720	
20		
22		
23 24		
25		
26 27		
28		
29		
30 31		
32		
33 34		
35		
36 37		
38		
39		
40 41		
42		
43 44		
45		
46 47		
47 48		
49		
50 51		
52		
53 54		
54 55		
56		
57 58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Note: GP – general practitioner; Wgt – weight; Ht – height; BP – blood pressure; FFQ – food frequency questionnaire; OGTT – Oral glucose tolerance test



ion. Fig 2. AUC calculation.




Fig 3. PRISMA Flow Diagram exemplar

		BMJ Open cop	Page 36
		BMJ Open Standard Protocol Items: Recommendations for Interventional Trials	
SPIRIT 2013 Check	dist: Reco	ommended items to address in a clinical trial protocol and related documents*	
Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormation	t Super text an	
Title	1	Descriptive title identifying the study design, population, interventions, and, if apple able, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	23
Roles and	5a	Names, affiliations, and roles of protocol contributors	1&3
responsibilities	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, managemere, adalysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee endpoint adjudication committee, data management team, and other individuals or groups over ceing the trial, if applicable (see Item 21a for data monitoring committee)	20-21
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	1

Page	37 of 39		BMJ Open BMJ Open-202	
1 2	Introduction		-2023- ight, i	
3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including swommary of relevant4-6 studies (published and unpublished) examining benefits and harms for each intergent on	
6 7		6b	Explanation for choice of comparators	
8 9	Objectives	7	Specific objectives or hypotheses6	
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factory single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, explorations)777	
14 15	Methods: Participa	nts, inte	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of by the study settings (eg, community clinic, academic hospital) and list of by the study sites can be obtained	_
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and88 individuals who will perform the interventions (eg, surgeons, psychotherapists)	_
22 23 24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including hoge and when they will be10 administered	_
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial parti قَعْنُهُمْ (eg, drug doseN/A change in response to harms, participant request, or improving/worsening diseas جَعْنُ جَ	_
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for the magnitoring adherence12-16 (eg, drug tablet return, laboratory tests)	-
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_
34 35 36 37 38 39	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,16-17 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	-
40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for7&fig 1 participants. A schematic diagram is highly recommended (see Figure)	-
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

Page 38 of 39

3

46

			BMJ Open Corpo		Page 3
1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was betermined, including	7-8	
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	9	
6 7	Methods: Assignm	ent of i	nterventions (for controlled trials)		
8 9	Allocation:		ses reig		
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random not be predictability of a random sequence, details of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a point of a random sequence (eg, blocking) should be provided in a separate document that is unavailable to the second of a point of a poi	9	
16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequered, opaque, sealed envelopes), describing any steps to conceal the sequence until in the mentions are assigned	9	
20 21 22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	9-10	
23 24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome	9	
20 27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	9-10	
30 31 32	Methods: Data coll	ection,	management, and analysis		
33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9	
38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	13-16	
42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		;

Page	39 of 39		BMJ Open cop	
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality _ (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	19-20
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where details of the	17-18
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	18-19
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as random and any statistical methods to handle missing data (eg, multiple imputation)	18-19
14 15	Methods: Monitorin	ng	t and f	
16 17 18 19 20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and report	20
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim _ results and make the final decision to terminate the trial	19-20
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously eported adverse	19-20
28 29 30 31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	N/A
32 33	Ethics and dissemi	nation	ologies.	
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	2&19
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility creations, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial regiseries, journals, regulators)	19
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		BMJ Open S S S S S S S S S S S S S S S S S S S	Page 4
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and, Automatic for the set of	9
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillarys	_N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected area and maintained	_19
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall the study site2	4-25
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contracted al agreements that	_25
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those suffer harm from trial	_N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results data sharing arrangements), including any publication restrictions	21-22
	31b	Authorship eligibility guidelines and any intended use of professional writers	_N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level datas and statistical code	_N/A
Appendices		techr	
Informed consent materials	32	Model consent form and other related documentation given to participants and aug of surrogates	_N/A
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for ge	_N/A
Amendments to the p	orotoco	I that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification c I should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Common	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	5